<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment, prognosis, and follow-up of acute pulmonary embolism in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment, prognosis, and follow-up of acute pulmonary embolism in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment, prognosis, and follow-up of acute pulmonary embolism in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aaron S Weinberg, MD, MPhil
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Parth Rali, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Korilyn S Zachrison, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute pulmonary embolism (PE) is a common and sometimes fatal disease with a variable clinical presentation. It is critical that therapy be administered in a timely fashion [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p>
         The treatment, prognosis, and follow-up of patients with acute PE are reviewed here. The epidemiology, pathophysiology, clinical presentation, and diagnosis of PE, as well as detailed discussions of anticoagulation and thrombolysis in patients with PE are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120060 utd-content-120061">
          (Related Pathway(s):
          <a class="utd-content-120060" href="/pathway/120060?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults
          </a>
          and
          <a class="utd-content-120061" href="/pathway/120061?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults
          </a>
          .)
         </span>
        </p>
        <p>
         The approach to treatment outlined in this topic is, in general, consistent with strategies outlined by several international societies including the American College of Chest Physicians, the American College of Physicians, the European Society of Cardiology, the European Respiratory Society, the American Society of hematology, and others [
         <a href="#rid6">
          6-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INITIAL APPROACH AND RESUSCITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial approach to patients with
         <strong>
          suspected
         </strong>
         PE should focus upon stabilizing the patient while clinical evaluation and definitive diagnostic testing are ongoing [
         <a href="#rid11">
          11
         </a>
         ]. Anticoagulation should be initiated even prior to confirming the diagnosis of PE if risk benefit regarding suspicion of PE and risk of bleeding appear favorable. Once diagnosis is confirmed, risk stratification is crucial. It is also important to triage and risk stratify the patients to identify which patients may benefit from inter hospital transfer.
        </p>
        <p class="headingAnchor" id="H276577963">
         <span class="h2">
          Assess hemodynamic stability
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial approach to patients with suspected PE depends upon whether the patient is hemodynamically stable or unstable as shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults", section on 'Nomenclature'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodynamically unstable PE (ie, high-risk or "massive" PE) is that which presents with hypotension; hypotension is defined as a systolic blood pressure (BP) &lt;90 mmHg for a period &gt;15 minutes or a drop in systolic blood pressure substantially below baseline (generally a drop of &gt;40 mmHg, hypotension requiring vasopressors, or clear evidence of shock). Importantly, these high-risk patients are a heterogeneous group [
         <a href="#rid8">
          8
         </a>
         ] with the extremely unstable patients suffering cardiac arrest.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodynamically stable PE is defined as PE that does not meet the definition of hemodynamically unstable PE. These patients are also a very heterogeneous group ranging from patients with small PE, stable BP, normal right ventricular size and function and normal biomarkers, with a normal simplified Pulmonary Embolism Severity Index (sPESI) ("low risk") to those patients with extensive emboli with tachycardia, right ventricular dysfunction, abnormal biomarkers, and borderline BP (ie, intermediate risk "submassive" PE). Based upon the European Society of Cardiology (ESC) guidelines [
         <a href="#rid8">
          8
         </a>
         ], these patients have been categorized as "intermediate-low risk" (abnormal right ventricular function
         <strong>
          or
         </strong>
         elevated serum troponin) and intermediate-high risk (abnormal right ventricular function
         <strong>
          and
         </strong>
         elevated serum troponin).
        </p>
        <p>
        </p>
        <p>
         Importantly, patients may become hemodynamically stable following resuscitation, or become unstable during the evaluation and early treatment period, both of which necessitate rapid redirection of therapeutic strategies. It is important to point out that proximal deep venous thrombosis (DVT) is associated with adverse PE-related outcomes. Even though not part of current classification system, it is a very important tool in risk stratification [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H366903997">
         <span class="h3">
          Hemodynamically stable
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with PE are hemodynamically stable upon presentation [
         <a href="#rid14">
          14,15
         </a>
         ]. The initial approach should focus upon general supportive measures while the diagnostic evaluation is ongoing; supportive measures include the following (see
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         and
         <a class="local">
          'Hemodynamically stable patients'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral intravenous access with or without intravenous fluids (see
         <a class="local">
          'Hemodynamic support'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxygen supplementation (see
         <a class="local">
          'Respiratory support'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric anticoagulation depending upon the clinical suspicion for PE, risk of bleeding, and expected timing of definitive diagnostic tests (see
         <a class="local">
          'Empiric anticoagulation'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H276577990">
         <span class="h3">
          Hemodynamically unstable
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small percentage of patients with PE present with hemodynamic instability or shock (&lt;10 percent, ie, high-risk or "massive" PE). When patients with suspected PE present with hypotension, initial support should focus upon restoring perfusion and vasopressor support, as well as oxygenation and, if necessary, stabilizing the airway with intubation and mechanical ventilation [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Hemodynamic support'
         </a>
         below and
         <a class="local">
          'Respiratory support'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults", section on 'Nomenclature'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients who become hemodynamically stable following resuscitation and in whom the clinical suspicion for PE is high, we prefer immediate anticoagulation with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         and prompt imaging for definitive diagnosis (usually computed tomographic pulmonary angiography [CTPA]). For patients with a moderate or low suspicion for PE, the use of empiric anticoagulation depends upon the timing of diagnostic testing. Diagnostic testing in patients with suspected PE is presented elsewhere. (See
         <a class="local">
          'Empiric anticoagulation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Hemodynamically stable patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a high clinical suspicion for PE who are hemodynamically unstable (ie, systolic blood pressure &lt;90 mmHg for &gt;15 minutes, hypotension requiring vasopressors, or clear evidence of shock), and in whom transfer to radiology for a CTPA is considered unsafe, a portable perfusion scan can be done at some centers. When portable perfusion scanning or CTPA is not available or is unsafe, we prefer bedside echocardiography (transthoracic or transesophageal) to obtain a presumptive diagnosis of PE (right ventricle enlargement/hypokinesis, regional wall motion abnormalities that spare the right ventricular apex [McConnell's sign], or visualization of clot) prior to the empiric administration of systemic thrombolytic therapy (ie, reperfusion therapy). If bedside echocardiography is delayed or unavailable, the use of thrombolytic therapy as a life-saving measure should be individualized; if not used, the patient should receive empiric anticoagulation. The initiation of anticoagulation should not be delayed while considering other, more aggressive interventional therapies. We suggest a similar approach for select patients with known PE whose course becomes complicated by hypotension during anticoagulation in whom the suspicion for recurrent PE despite anticoagulation is high. Some clinicians use bedside ultrasonography to demonstrate evidence of DVT, which may raise the suspicion for PE in the absence of another reasonable diagnosis and facilitate decision-making. (See
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with suspected PE who remain hemodynamically unstable and the clinical suspicion is low or moderate, the approach to empiric anticoagulation should be the same as for patients who are hemodynamically stable; empiric thrombolysis is not justified in this population.
        </p>
        <p>
        </p>
        <p>
         The echocardiographic findings suggestive of PE and the diagnostic approach to hemodynamically unstable patients, as well as the indications for thrombolytic therapy and its alternative, embolectomy, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Echocardiography'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Hemodynamically unstable patients'
         </a>
         and
         <a class="local">
          'Embolectomy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Hemodynamically unstable patients (high-risk pulmonary embolism)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1474096660">
         <span class="h4">
          Pulmonary embolism response teams (PERT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to administer thrombolysis is strongly influenced by additional clinical factors. For example, while a patient with proven PE-induced shock who is unconscious requiring very high doses of vasopressors is a candidate for immediate intravenous thrombolytic therapy, a patient who has low blood pressure for 20 minutes but who is awake, alert, and comfortable, with low oxygenation requirement might be considered for anticoagulation alone, or a catheter-based interventional procedure. Thus, when feasible, it is prudent to adopt a multidisciplinary approach to facilitate management of hemodynamically unstable patients with PE as well as selected patients with intermediate-high risk PE; some centers have incorporated a "pulmonary embolism response team" (PERT) to facilitate the process [
         <a href="#rid15">
          15-18
         </a>
         ].
        </p>
        <p>
         There are limited data that describe the impact of PERT. One single center retrospective study examined outcomes in patients with PE before and after the implementation of PERT [
         <a href="#rid19">
          19
         </a>
         ]. PERT was associated with a reduction in 30 day inpatient mortality (4.7 versus 8.5 percent), lower rates of major bleeding (8.3 versus 17 percent), shorter time to therapeutic anticoagulation (12.6 versus 16.3 hours), and decreased use of inferior vena cava filters (22.2 versus 16.4 percent) [
         <a href="#rid19">
          19
         </a>
         ]. The mortality benefit was most pronounced in the subgroup of patients with intermediate- and high-risk PE (5.3 versus 10 percent), suggesting that this population derive the greatest benefit from PERT. There was also an increased use of thrombolytic and catheter-based strategies that did not reach statistical significance. In contrast, in another single-center study of 2042 patients, among which 165 were evaluated by PERT, there was no difference in the mortality between the pre-PERT and post-PERT implementation phases [
         <a href="#rid20">
          20
         </a>
         ] and a meta-analysis of 22 studies reported that PERT lead to greater use of advanced therapies and shorter in-hospital stay but no survival benefit [
         <a href="#rid21">
          21
         </a>
         ]. The 2019 European Society of Cardiology (ESC) guidelines have included a discussion of the utility of PERT and given it a class IIa level C recommendation [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H286666805">
         <span class="h2">
          Initial therapies
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Respiratory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplemental oxygen should be administered to target an oxygen saturation ≥90 percent. Severe hypoxemia, hemodynamic collapse, or respiratory failure should prompt consideration of intubation and mechanical ventilation. Importantly, patients with coexistent right ventricle failure are prone to hypotension following intubation. Thus, in this population, it may be prudent to consult an expert in cardiovascular anesthesia and high plateau pressures should be avoided. The principles of intubation, mechanical ventilation, and extracorporeal membrane oxygenation (which has been used successfully in severely ill patients with refractory hypoxemia and/or hypotension), are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/260.html" rel="external">
          "Direct laryngoscopy and endotracheal intubation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">
          "Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Indications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Hemodynamic support
         </span>
         <span class="headingEndMark">
          —
         </span>
         The precise threshold that warrants hemodynamic support depends upon the patient's baseline blood pressure and whether there is clinical evidence of hypoperfusion (eg, change in mental status, diminished urine output). In general, we prefer small volumes of intravenous fluid (IVF), usually 250 to 500 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , followed by vasopressor therapy should perfusion fail to respond to IVF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous fluid
         </strong>
         – IVF is first-line therapy for patients with hypotension. However, in patients with right ventricular (RV) dysfunction, limited data suggest that aggressive fluid resuscitation is not beneficial, and may be harmful [
         <a href="#rid22">
          22-26
         </a>
         ]. The rationale for limiting IVF administration comes from preclinical studies and one small observational study in humans, which reported that small volumes of IVF increase the cardiac index in patients with PE, while excessive amounts of IVF result in RV overstretch (ie, RV overload), RV ischemia, and worsening RV failure. The patient's volume status should be carefully assessed as this could influence the approach to fluid administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasopressors
         </strong>
         – Intravenous vasopressors are administered when adequate perfusion is not restored with IVF. The optimal vasopressor for patients with shock due to acute PE is unknown, but
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         is generally preferred  (
         <a class="graphic graphic_table graphicRef63100" href="/z/d/graphic/63100.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid23">
          23,27-29
         </a>
         ]. Options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Norepinephrine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          Norepinephrine
         </a>
         is the most frequently utilized agent in this population because it is effective and less likely to cause tachycardia [
         <a href="#rid23">
          23
         </a>
         ]. Other alternatives include
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , but tachycardia, which can exacerbate hypotension, can occur with these agents [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dobutamine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          Dobutamine
         </a>
         is sometimes used to increase myocardial contractility in patients with circulatory shock from PE. However, it also results in systemic vasodilation which worsens hypotension, particularly at low doses [
         <a href="#rid28">
          28,29
         </a>
         ]. To mitigate this effect, we typically initially add
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         to dobutamine; as the dose of dobutamine is increased, the effects of dobutamine-induced myocardial contractility exceed those of vasodilation, potentially allowing norepinephrine to be weaned off.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          Isoproterenol
         </a>
         , amrinone, and
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         have been investigated in animal models, but have not proven useful for hypotension due to acute PE [
         <a href="#rid30">
          30,31
         </a>
         ]. Physiologic properties and use of vasopressors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">
          "Use of vasopressors and inotropes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Empiric anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of empiric anticoagulation depends upon the risk of bleeding, clinical suspicion for PE (
         <a class="calc calc_professional" href="/z/d/html/13446.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef54767" href="/z/d/graphic/54767.html" rel="external">
          table 2
         </a>
         ) and the expected timing of diagnostic tests [
         <a href="#rid5">
          5,26
         </a>
         ]. There is no optimal prediction tool for assessing bleeding risk in patients with PE. Similarly, while many experts propose use of the Wells score to assess the risk of PE, careful clinical judgment is acceptable and many experts use gestalt estimates, the details of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Determining the pretest probability of pulmonary embolism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'
         </a>
         .)
        </p>
        <p>
         One strategy is shown below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low risk for bleeding – Patients without risk factors for bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ) have a three-month bleeding risk of &lt;2 percent; in such patients, empiric anticoagulation may be considered in the following patient groups:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A high clinical suspicion for PE (eg, Wells score &gt;6)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A moderate clinical suspicion for PE (eg, Wells score 2 to 6), in whom the diagnostic evaluation is expected to take longer than four hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A low clinical suspicion for PE (eg, Wells score &lt;2), if the diagnostic evaluation is expected to take longer than 24 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unacceptably high risk for bleeding – For patients with
         <strong>
          absolute contraindications
         </strong>
         to anticoagulant therapy (eg, recent surgery, hemorrhagic stroke, active bleeding) or those assessed by their clinician to be at an unacceptably
         <strong>
          high
         </strong>
         risk of bleeding (eg, aortic dissection, intracranial or spinal cord tumors), empiric anticoagulation should
         <strong>
          not
         </strong>
         be administered. The diagnostic evaluation should be expedited so that alternate therapies (eg, inferior vena cava filter, embolectomy) can be initiated if PE is confirmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate risk for bleeding – Patients with one or more risk factors for bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ) have a moderate (&gt;3 percent) to high (&gt;13 percent) risk of bleeding. In such patients, empiric anticoagulant therapy may be administered on a case-by-case basis according to the assessed risk-benefit ratio and the values and preferences of the patient. Additionally, use of these bleeding estimates should
         <strong>
          not
         </strong>
         preclude clinical judgment when making a decision to anticoagulate in this population. As an example, we might empirically anticoagulate a patient with moderate risk of bleeding if they have a high clinical suspicion for PE, severe respiratory compromise, or an expected delay for the insertion of a vena caval filter.
        </p>
        <p>
        </p>
        <p>
         Typically, menstruation, epistaxis, and the presence of minor hemoptysis are not contraindications to anticoagulation but should be monitored during anticoagulant therapy. (See
         <a class="local">
          'Monitoring and follow-up'
         </a>
         below.)
        </p>
        <p>
         It is common that patients with PE may have hemoptysis largely due to pulmonary infarction, and anticoagulation should not be stopped or considered contraindicated for that reason. The optimal agent for empiric anticoagulation depends upon the presence or absence of hemodynamic instability, the anticipated need for procedures or thrombolysis, and the presence of risk factors and comorbidities  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 4
         </a>
         ). As an example, low molecular weight (LMW) heparin may be chosen for patients with hemodynamically stable PE who do not have renal insufficiency in whom rapid onset of anticoagulation needs to be guaranteed (ie, therapeutic levels are achieved with four hours). While
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         may be preferred by most experts in patients who are hemodynamically unstable in anticipation of a potential need for thrombolysis or embolectomy, some trials with catheter-based treatments (lysis and embolectomy) allowed patients on background LMW heparin [
         <a href="#rid32">
          32,33
         </a>
         ]. Direct thrombin and factor Xa inhibitors should
         <strong>
          not
         </strong>
         be used in hemodynamically unstable patients. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DEFINITIVE THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H348157128">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom the diagnostic evaluation excludes PE (see
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         ), anticoagulant therapy should be discontinued if it was initiated empirically, and alternative causes of the patient's symptoms and signs should be sought  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ).
        </p>
        <p>
         For patients in whom the diagnostic evaluation confirms PE, we suggest an approach that is stratified according to whether the patient is hemodynamically stable or unstable  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ). At any time, the strategy may need to be redirected as complications of PE or therapy arise. (See
         <a class="local">
          'Hemodynamically stable patients'
         </a>
         below and
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         below.)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120060 utd-content-120061">
          (Related Pathway(s):
          <a class="utd-content-120060" href="/pathway/120060?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults
          </a>
          and
          <a class="utd-content-120061" href="/pathway/120061?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults
          </a>
          .)
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Hemodynamically stable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients in this group are heterogeneous and have a wide range of presentations as well as variable risk of recurrence and decompensation; it includes those with low-risk, intermediate-low risk, and intermediate-high risk PE.
        </p>
        <p>
         We suggest the following approach for most hemodynamically stable (ie, normotensive) patients with low-risk and intermediate-low risk PE  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those in whom the risk of bleeding is low, anticoagulant therapy is indicated. (See
         <a class="local">
          'Anticoagulation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those who have contraindications to anticoagulation or have an unacceptably high bleeding risk, placement of an inferior vena cava (IVC) filter should be performed. (See
         <a class="local">
          'Inferior vena cava filters'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those in whom the risk of bleeding is moderate or high, therapy should be individualized according to the assessed risk-benefit ratio and values and preferences of the patient. As an example, a patient &gt;75 years who is at risk of falling is not an ideal candidate for anticoagulation; anticoagulation may be considered if a vena cava filter cannot be placed (eg, inability to access the IVC due to extensive thrombus or tumor). (See
         <a class="local">
          'Empiric anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It should be noted that when PE is proven and anticoagulation is contraindicated, an IVC filter is still indicated, whether the PE is small or extensive and even in the absence of residual deep venous thrombosis (DVT).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most hemodynamically stable patients, we recommend
         <strong>
          against
         </strong>
         thrombolytic therapy (eg, low risk patients).
        </p>
        <p>
        </p>
        <p>
         Hemodynamically
         <strong>
          stable
         </strong>
         (ie, normotensive) patients with intermediate-risk/submassive PE who are anticoagulated, should be monitored closely for deterioration. Thrombolysis and/or catheter-based therapies may be considered on a case-by-case basis when the benefits are assessed by the clinician to outweigh the risk of hemorrhage. Examples of such patients include those who have a large clot burden, severe RV enlargement/dysfunction, high oxygen requirement, and/or are severely tachycardic  (
         <a class="graphic graphic_table graphicRef82171" href="/z/d/graphic/82171.html" rel="external">
          table 5
         </a>
         ). The details of such therapies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Systemic infusion (full-dose thrombolytic)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H348157817">
         <span class="h3">
          Anticoagulation
         </span>
        </p>
        <p class="headingAnchor" id="H389850409">
         <span class="h4">
          Indications and duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticoagulant therapy is indicated for patients with PE in whom the risk of bleeding is low:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial anticoagulation
         </strong>
         – Initial anticoagulant therapy is administered as soon as possible to quickly achieve therapeutic anticoagulation. A detailed discussion of agent selection and patient selection for outpatient anticoagulation is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="local">
          'Outpatient anticoagulation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term anticoagulation (after discharge)
         </strong>
         – All patients are anticoagulated for a minimum of three months. Agent selection and duration of long-term anticoagulation in patients with PE and DVT are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indefinite anticoagulation
         </strong>
         – Select patients with PE are candidates for indefinite anticoagulation. Patient selection depends upon the nature of the event (ie, provoked or unprovoked), the presence of risk factors (eg, transient or persistent), the estimated risk of bleeding and recurrence, as well as patient preferences and values (eg, occupation, life expectancy, burden of therapy), and trials that support a benefit. The rationale and indications for indefinite anticoagulation are described separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H286668969">
         <span class="h4">
          Outpatient anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In select patients with PE, outpatient therapy can be administered by giving the first dose of anticoagulant in the hospital or urgent care center, with the remaining doses given at home. The decision to treat as an outpatient should be made in the context of the patient's clinical condition, understanding of the risk-benefit ratio, and their preferences. Although the ideal candidate is poorly defined, guideline groups, several randomized trials, and meta-analyses suggest that, in patients with PE, outpatient anticoagulation is safe and effective in carefully selected patients with all of the following features [
         <a href="#rid5">
          5,34-45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low risk of death – defined as Pulmonary Embolism Severity Index (PESI) class I or II  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         ), or simplified PESI (sPESI) score = 0 (see
         <a class="local">
          'Prognostic models'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No requirement for supplemental oxygen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No requirement for narcotics for pain control
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No respiratory distress
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal pulse and blood pressure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No recent history of bleeding or risk factors for bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No serious comorbid conditions (eg, ischemic heart disease, chronic lung disease, liver or renal failure, thrombocytopenia, or cancer)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal mental status with good understanding of risk and benefits, are not needle averse (if low molecular weight [LMW] heparin chosen), and have good home support (eg, do not live alone, have access to a telephone and clinician, can return to the hospital quickly if there is clinical deterioration)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of concomitant DVT (a high clot burden in the lower extremities may increase the risk of recurrence, death, or warrant additional therapy)
        </p>
        <p>
        </p>
        <p>
         Support for outpatient therapy or early discharge following a brief inpatient stay is derived from randomized studies and meta-analyses with flawed methodology [
         <a href="#rid9">
          9,38,40,42
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One open label, multicenter trial randomly assigned 344 patients with symptomatic PE and a low risk of death (PESI I/II;  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         )) to receive either inpatient (intravenous heparin followed by
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) or outpatient (subcutaneous LMW heparin followed by warfarin) therapy [
         <a href="#rid38">
          38
         </a>
         ]. Compared with inpatients, patients treated as an outpatient had a slightly higher rate of recurrent venous thromboembolism (VTE; 0.6 percent versus 0 percent) and major bleeding events (1.8 percent versus 0 percent) at 90 days that was not statistically significant. Mortality was no different between the groups (0.6 percent). The mean length of stay was 0.5 days for outpatients and 3.9 days for inpatients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2013 meta-analysis of 21 studies compared patients at low risk of death who were anticoagulated for PE as an outpatient (discharged within 24 hours) with patients who were treated as an inpatient and discharged after 72 hours (randomized and observational studies were included) [
         <a href="#rid40">
          40
         </a>
         ]. Compared with inpatient anticoagulation, outpatient anticoagulation was not associated with a statistically significant difference in the rate of recurrent VTE (1.7 versus 1.2 percent) and mortality (1.9 versus 0.74 percent), or major bleeding events (0.97 versus 1 percent); However, although absolute rates of recurrent VTE and death were higher with outpatient treatment, there was significant population and therapeutic regimen heterogeneity among the included studies, limiting the interpretation of the results. A 2018 analysis of two randomized trials reported low quality evidence that there was no difference in 30- or 90-day mortality, major bleeding, or recurrence between low risk patients with acute PE who were treated as an inpatient or outpatient [
         <a href="#rid46">
          46
         </a>
         ]. In a 2021 meta-analysis of 14 studies of patients with low-risk PE, there was no difference in the mortality or recurrence rate or rate of major bleeding among patients treated as an outpatient or inpatient [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis of 1127 patients reported that the 14 day rate of adverse events (recurrent VTE, major bleeding, or death) was 3 percent for outpatients compared with 13 percent for inpatients and the three-month rate was 7 and 22 percent, respectively [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another randomized trial of 114 patients with PE who were discharged on
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and were at low risk of death the LOS was significantly reduced in early discharge patients compared with those who were admitted (34 versus 5 hours) [
         <a href="#rid48">
          48
         </a>
         ]. At three months, there were no bleeding events, recurrent VTE, or deaths.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective analysis of 525 patients with PE who were discharged early and treated with
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         , only three patients (0.6 percent) developed symptomatic non-fatal VTE recurrence at three months follow-up and bleeding rates were low (1.2 percent) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The ideal agent is unknown. Agent selection for outpatient anticoagulant therapy in patients with PE is similar to that for DVT. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         .)
        </p>
        <p>
         Despite the fact that outpatient anticoagulation has been shown to be safe, this practice may be uncommon. One retrospective review of 746 patients with PE who were potentially eligible for anticoagulation at home, reported that only 1.7 percent were treated at home and only 16 percent were discharged within two days [
         <a href="#rid50">
          50
         </a>
         ]. However, clinician education may change this practice. As an example, in one trial of 1763 patients diagnosed with PE in the ED, an electronic intervention built into the electronic health record increased the number of patients who could be discharged to home (17 percent versus 28 percent) without increasing the risk of return visits to the ED, recurrent VTE, or mortality [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1160626226">
         <span class="h4">
          Patients with subsegmental PE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The increasing use of computed tomography (CT) has led to the increased diagnosis of incidental (asymptomatic) PE and small subsegmental PE (SSPE)  (
         <a class="graphic graphic_figure graphicRef104076" href="/z/d/graphic/104076.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         One observational study reported that 15 percent of patients with symptomatic PE have SSPE [
         <a href="#rid52">
          52
         </a>
         ]. The true proportion of patients with asymptomatic SSPE is unknown [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Although the clinical relevance of SSPE is unknown, a single subsegmental defect probably does not have the same clinical outcome as a single segmental or lobar PE or multiple SSPE. A retrospective review of 222 patients with PE, 36 percent of whom had SSPE, reported that 87 percent were systemically anticoagulated while the remaining were not anticoagulated due to bleeding or poor prognosis at the time of diagnosis [
         <a href="#rid54">
          54
         </a>
         ]. Adverse events were similar between SSPE patients and patients with more proximal emboli. (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults", section on 'Nomenclature'
         </a>
         .)
        </p>
        <p>
         In patients with SSPE, the incidence of VTE recurrence is unclear but may be higher than that in the general population. While older retrospective studies suggested minimal recurrence, studies were flawed [
         <a href="#rid55">
          55-57
         </a>
         ]. However, in the largest prospective study to date of 292 patients with isolated SSPE and no lower-extremity DVT who were managed without anticoagulation, the recurrence rate was 3.1 percent at 90 days, (ie, higher than the expected rate in the general population of approximately 1 percent or less) [
         <a href="#rid58">
          58
         </a>
         ]. Rates were higher in those with multiple SSPEs compared with a single isolated PE (5.7 versus 2.1 percent) and higher in older patients compared with those younger than 65 years (5.5 versus 1.8 percent). No fatalities were reported. However, this study was stopped early for benefit, which may have influenced the results.
        </p>
        <p>
         Whether or not patients with SSPE should be anticoagulated is controversial [
         <a href="#rid9">
          9,59
         </a>
         ]. Practice varies widely; some experts anticoagulate all patients with SSPE, regardless of whether or not symptoms are present, while other experts avoid anticoagulation in a minority of individuals (especially if a more convincing etiology is discovered on CT for the patients' symptoms) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Our approach to anticoagulating patients with SSPE is the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We believe that most patients with SSPE should be anticoagulated similarly to those who present with symptomatic or large lobar defects [
         <a href="#rid5">
          5,9
         </a>
         ]. This is particularly important when VTE is unprovoked and persistent risk factors for VTE such as active cancer and acute hospitalization with prolonged immobility, are present; defects are multiple; symptoms are present; and/or when patients have limited cardiorespiratory reserve. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal duration of anticoagulation is unknown but similar to patients with segmental or lobar PE, patients with SSPE should be treated for a minimum of three months. Anticoagulant therapy beyond that period should be individualized, the details of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Incidental subsegmental PE without identifiable risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Experts also agree that a small subset of patients with a single small defect (ie, seen on one image) in whom there is no evidence of proximal lower extremity DVT or evidence of thrombus elsewhere (eg, upper extremity clot) may reasonably opt for no anticoagulation, provided the risk of recurrence is considered low and patients are monitored appropriately [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional findings that may support this decision include those in whom a false positive test is suspected, the absence of persistent risk factors, those with preserved baseline cardiorespiratory function, and/or those in whom a low pretest probability and normal D-dimer is present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When clinical surveillance is chosen, we suggest serial testing with bilateral proximal compression ultrasonography (CUS) of the lower extremities in two weeks to look for evidence of proximal thrombus. We also have a low threshold to repeat diagnostic imaging for PE should symptoms persist or recur. This strategy is based upon the rationale that serial CUS has been reported to be safe in patients with nondiagnostic testing for PE (eg, indeterminate or low probability ventilation perfusion scanning); details regarding this strategy are described separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Lower-extremity ultrasound with Doppler'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite support for this strategy, many clinicians are adopting the practice [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13594723">
         <span class="h3">
          Inferior vena cava filter
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, an inferior vena cava (IVC) filter is not necessary. For most patients with PE in whom anticoagulation is contraindicated, or patients in whom the risk of bleeding is unacceptably high, IVC filter should be placed. Similarly, an IVC filter is appropriate in patients who develop contraindications while on anticoagulation; however, placement in this population depends upon the planned duration of anticoagulation and risk of recurrence when anticoagulation is discontinued. Another more unusual indication for an IVC filter is recurrence despite therapeutic anticoagulation; a decision may be more difficult in patients who recur quickly after the onset of anticoagulation. Retrievable filters should be used such that once the contraindication has resolved, the filter can be removed and patients should be anticoagulated. The efficacy of IVC filters, their placement and complications, are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         and
         <a class="local">
          'Inferior vena cava filters'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Inferior vena cava filter'
         </a>
         .)
        </p>
        <p>
         When contraindications to anticoagulation are present in acute PE, an IVC filter should be placed even in the absence of proven lower extremity thrombus. Thrombus may remain undetected in the pelvis or calf veins or clot can quickly reform in the leg veins after embolization.
        </p>
        <p>
         However, the decision to place an IVC filter, most of which are infrarenal, is modified in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has confirmed extensive upper extremity thrombosis in the absence of lower extremity thrombosis, an IVC filter will not be effective; and a superior vena caval filter may be useful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the thrombus is in the renal vein (identified by the initial CT angiogram or during placement of the IVC filter), a suprarenal filter is appropriate.
        </p>
        <p>
        </p>
        <p>
         Data describing outcomes in patients with PE who have IVC filters placed are limited:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial (PREPIC2) reported outcomes in 399 patients with
         <strong>
          severe PE
         </strong>
         (eg, older patients &gt;75 years, active cancer, signs of right ventricle dysfunction, chronic respiratory insufficiency) who received either standard anticoagulation alone or anticoagulation plus an IVC filter that was retrieved at three months [
         <a href="#rid61">
          61
         </a>
         ]. At three months, the addition of an IVC filter to anticoagulation did not alter the rate of PE recurrence (1.5 versus 3 percent), DVT recurrence (0.5 percent), or mortality (7.5 versus 6 percent). The lack of benefit associated with IVC filter placement was persistent at six months. The rate of filter complications (eg, thrombosis) was low (&lt;2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data derived from the Nationwide Inpatient Sample reported that the insertion of an IVC filter in hemodynamically stable patients with PE did not improve in-hospital mortality but was associated with a lower in-hospital case fatality rate among unstable patients who received thrombolytic therapy (8 versus 18 percent) as well as unstable patients who did not receive thrombolytic therapy (33 versus 51 percent) [
         <a href="#rid62">
          62,63
         </a>
         ]. Another database analysis of over 13,000 patients with PE who were treated with either thrombolytic or anticoagulant therapy reported a reduction in in-hospital mortality in those who were adjunctively treated with an IVC filter compared with those who did not receive a filter (3 versus 5 percent) [
         <a href="#rid64">
          64
         </a>
         ]. However, both of these studies are intrinsically flawed.
        </p>
        <p>
        </p>
        <p>
         One of the frequent anecdotal indication uses of IVC filter placement is to prevent follow-up PE in patients who have large clot burden in the pulmonary arteries with proximal DVT. Most of these patients may be in the intermediate risk PE category. Such practices should ideally be avoided, and if there is clinical concern, a multidisciplinary approach with PERT team and potential treatment with catheter-based treatments (PE or DVT) can be considered.
        </p>
        <p class="headingAnchor" id="H286667407">
         <span class="h2">
          Hemodynamically unstable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with PE who are hemodynamically unstable or who become unstable due to recurrence despite anticoagulation, we suggest more aggressive therapies (ie, reperfusion therapies) than anticoagulation including the following  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombolytic therapy is indicated in most patients, provided there is no contraindication  (
         <a class="graphic graphic_table graphicRef95035" href="/z/d/graphic/95035.html" rel="external">
          table 7
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Hemodynamically unstable patients (high-risk pulmonary embolism)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Systemic infusion (full-dose thrombolytic)'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Embolectomy is appropriate for those in whom thrombolysis is either contraindicated or unsuccessful (surgical or catheter-based) (see
         <a class="local">
          'Embolectomy'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H117884119">
         <span class="h3">
          Reperfusion therapy
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h4">
          Thrombolytic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic thrombolytic therapy is a widely accepted treatment for patients with PE who present with, or whose course is complicated by, hemodynamic instability. This therapy can be delivered more quickly than can be done via a catheter-based method; if there are no contraindications to systemic thrombolysis and the indication for reperfusion therapy is clear, the patient should not wait until an operator or catheterization service lab is available. Catheter-directed thrombus removal with or without thrombolysis can also be administered in select patients (eg, those at high risk of bleeding and those who have failed systemic thrombolysis). The indications, contraindications, agents, administration, and outcomes of systemic and catheter-directed thrombolysis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="local">
          'Catheter-directed modalities'
         </a>
         below.)
        </p>
        <p>
         For those in whom systemic thrombolysis is unsuccessful, the optimal therapy is unknown. Options include repeat systemic thrombolysis, catheter-directed thrombolysis, or catheter or surgical embolectomy, the choice of which is dependent upon available resources and local expertise. (See
         <a class="local">
          'Embolectomy'
         </a>
         below.)
        </p>
        <p>
         A prediction score for the risk of major bleeding during thrombolysis ("BACS score")has been proposed but requires further validation before it can be routinely used [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1309084381">
         <span class="h4">
          Embolectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Embolectomy is indicated in patients with hemodynamically unstable PE in whom thrombolytic therapy is contraindicated. It is also a therapeutic option in those who fail thrombolysis. Emboli can be removed surgically or using a catheter. The choice between these options depends upon available expertise, the presence or absence of a known diagnosis of PE, underlying comorbidities, and the anticipated response to such therapies. As an example, when a patient has severe hemodynamic instability and standard dose thrombolysis is contraindicated, catheter-directed techniques may be preferred if the expertise is available. One advantage of this approach is that both diagnostic and therapeutic interventions can be applied simultaneously.
        </p>
        <p class="headingAnchor" id="H286668314">
         <span class="h5">
          Catheter-directed modalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several catheter-directed techniques are available. Studies have been limited by small sample size and the inclusion of heterogeneous populations (patients who are hemodynamically stable and unstable, patients with and without contraindications to thrombolysis) as well as the adjunctive administration of catheter-directed thrombolytic agents. Nearly all modern-day catheter-directed thrombolysis trials have utilized tissue plasminogen activator (tPA). None has been demonstrated to have superiority over the other, such that the choice of technique is institution-dependent; an absolute contraindication to a thrombolytic agent means that if a catheter-directed technique is utilized, a catheter-directed clot extraction (ie, embolectomy) can be used. In our experience, catheter-directed techniques are most commonly utilized in patients with intermediate-high risk PE, although there is some experience with high-risk PE.
        </p>
        <p>
         Options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ultrasound-assisted thrombolysis –
         </strong>
         Catheter-directed high frequency ultrasound can enable the thrombolytic agent to better penetrate the embolus. Without thrombolytics, the technique has no proven benefit. This is the technique that is best supported by clinical trial data which are discussed separately [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Catheter-directed approaches'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Catheter-directed thrombolytic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheolytic embolectomy
         </strong>
         – Rheolytic embolectomy injects pressurized
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         through the catheter's distal tip while macerated thrombus is aspirated through a catheter port [
         <a href="#rid67">
          67-72
         </a>
         ]. In a series of 16 patients with massive or submassive PE who underwent rheolytic embolectomy, resolution of symptoms and improvement in right ventricle dysfunction were achieved in all patients [
         <a href="#rid71">
          71
         </a>
         ]. There were no in-hospital mortalities. Complications occurred in three patients (20 percent), two with acute kidney injury and one with an intraoperative cardiac arrest. Clinical success due to the intervention alone was unclear because two thirds of the cohort also received catheter-directed thrombolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because the catheter is large, the major disadvantage of rheolytic devices is that a venous cut-down (venotomy) is often required for insertion, which increases the risk of bleeding at the insertion site. In addition, the release of adenosine from disrupted platelets can lead to bradycardia, vasospasm, and hypoxia; similarly, red blood cell fragmentation can result in hemoglobinuria. These and other side effects have led to a boxed warning from regulatory agencies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rotational embolectomy
         </strong>
         – A rotating device at the catheter tip can be used to fragment the thrombus, while fragmented clot is continuously aspirated [
         <a href="#rid73">
          73-77
         </a>
         ]. In a series of 18 patients with shock due to PE, clinical success was achieved in 16 cases (89 percent), defined as improvement in oxygenation and blood pressure. The remaining patients had complications (eg, hemorrhage) and one patient died from refractory shock [
         <a href="#rid75">
          75
         </a>
         ]. Typically, rotational devices do not require venotomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suction embolectomy
         </strong>
         – Thrombus can be manually aspirated through a large-lumen catheter using an aspiration syringe and a hemostatic valve [
         <a href="#rid78">
          78,79
         </a>
         ]. In one study of 63 patients with mostly hemodynamically unstable PE who underwent suction embolectomy, 88 percent had a clinically significant reduction in clot burden and pulmonary artery pressure [
         <a href="#rid79">
          79
         </a>
         ]. Six percent of patients died and 14 percent had major bleeding. Clinical success due to the intervention alone was unclear because all patients also received catheter-directed thrombolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Technical difficulties with suction devices have limited their use but newer devices may be more successful [
         <a href="#rid32">
          32,80-82
         </a>
         ]. As an example, in a study (FLARE), 106 patients with documented PE and RV dysfunction (ie, intermediate risk PE), aspiration thrombectomy with a newer device resulted in improvement in RV function and pulmonary artery pressure with a complication rate of only 4 percent [
         <a href="#rid32">
          32
         </a>
         ]. There was one major bleed. Another retrospective study suggested improved in-hospital mortality and decreased ICU length of stay for patients with acute, central PE with a flow retrieval suction device [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More advanced catheters have been used for the removal of soft, fresh thrombi or for use during extracorporeal bypass. This applies most readily to large thromboemboli in the IVC, or right heart chambers. Such devices cannot easily access the pulmonary arteries to suction more distal emboli [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombus fragmentation
         </strong>
         – Mechanical disruption of the thrombus can be achieved by manually rotating a standard pigtail or balloon angioplasty catheter into the thrombus; small fragments move distally and thereby result in reduced pulmonary vascular resistance [
         <a href="#rid74">
          74,84,85
         </a>
         ]. While older studies report improved hemodynamic indices with fragmentation alone, newer studies have reported efficacy when fragmentation is combined with angioplasty, aspiration, and catheter-directed thrombolysis [
         <a href="#rid86">
          86
         </a>
         ]. Although rare, catheter-fragmentation can increase pulmonary vascular pressures likely via embolization of larger fragments into the distal branches of the pulmonary vascular bed [
         <a href="#rid87">
          87,88
         </a>
         ]. Consequently, aspiration of fragments is frequently concurrently performed to deal with this complication.
        </p>
        <p>
        </p>
        <p>
         Common to all catheter-assisted embolectomy techniques is the risk of pulmonary artery perforation; although rare, it can lead to pericardial tamponade and life-threatening hemoptysis, and is frequently catastrophic. Additional complications include hemorrhage and infection of venipuncture sites, worsening hemodynamic instability, cardiac arrest, and death, as well as device-specific adverse effects (listed above). Hemorrhagic side effects can be exacerbated by the co-administration of thrombolytic therapy.
        </p>
        <p class="headingAnchor" id="H286668552">
         <span class="h5">
          Surgical embolectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The usual indication for surgical embolectomy is hemodynamic instability due to acute PE for patients in whom thrombolysis (systemic or catheter-directed) is contraindicated, and is an option in those in whom thrombolysis has failed [
         <a href="#rid89">
          89-92
         </a>
         ]. Additional indications may include echocardiographic evidence of an embolus trapped within a patent foramen ovale, or present in the right atrium, or right ventricle [
         <a href="#rid93">
          93
         </a>
         ]. Surgical embolectomy is typically limited to large medical centers because an experienced surgeon and cardiopulmonary bypass are required. It has a high mortality, particularly in the older patient (2 to 46 percent) [
         <a href="#rid89">
          89-92,94-102
         </a>
         ]. Proximal emboli are amenable to surgical removal (ie, right ventricle, main pulmonary artery [PA], and extrapulmonary branches of the PA), whereas distal thrombus generally is not amenable to surgery (eg, intrapulmonary branches of the PA).
        </p>
        <p>
         In a retrospective database study, there was no difference in 30-day mortality with the 257 patients who underwent surgical embolectomy compared with 1854 patients with PE who underwent thrombolysis (15 versus 13 percent) [
         <a href="#rid103">
          103
         </a>
         ]. In an observational study of 40 patients with PE who had failed systemic thrombolysis, patients who underwent surgical embolectomy had fewer recurrent PE compared with patients who had repeat thrombolysis (0 versus 35 percent) [
         <a href="#rid95">
          95
         </a>
         ]. In addition, there were fewer deaths and fewer major bleeding complications associated with surgical embolectomy, which did not achieve statistical significance. In another series of 115 patients who underwent surgical embolectomy, compared with patients who had stable PE, those with unstable PE had a higher operative mortality (10 versus 4 percent) and worse survival (75 versus 93 percent) [
         <a href="#rid99">
          99
         </a>
         ]. Another retrospective series reported an in hospital mortality of only 2 percent and immediate improvement of right ventricle pressures that persisted at 30 months [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         Transesophageal echocardiography (TEE) should be performed before or during embolectomy to look for extrapulmonary thrombi (eg, in the right atrium, right ventricle, or vena cava). In a series of 50 patients with PE, intraoperative TEE detected extrapulmonary thrombi in 13 patients (26 percent), which altered the surgical management of five patients (10 percent) [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         Cardiac arrest upon presentation predicts mortality from surgical embolectomy [
         <a href="#rid89">
          89,105-108
         </a>
         ]. In one study of 36 patients with shock due to acute PE, but without cardiac arrest, the operative mortality associated with surgical embolectomy was 3 percent [
         <a href="#rid106">
          106
         </a>
         ]. In contrast, operative mortality was 75 percent among patients with acute PE who were resuscitated from a cardiac arrest and then underwent surgical embolectomy [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
         Complications include those associated with cardiac surgery and anesthesia, as well as embolectomy-specific complications such as perforation of the pulmonary artery and cardiac arrest. (See
         <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">
          "Postoperative complications among patients undergoing cardiac surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3937227993">
         <span class="h3">
          Extracorporeal membrane oxygenation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Venoarterial extracorporeal membrane oxygenation (V-A ECMO) has a growing role in management of patients with PE. V-A ECMO can be used as a sole therapy or bridge to definitive treatment (eg, surgical embolectomy or catheter-based treatments) in patients with PE. VA-ECMO can also be used as an initial strategy in patients with massive PE in whom systemic thrombolysis is contraindicated. Further details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H348157298">
         <span class="h2">
          Special populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the initial approach to the treatment of PE as well as the treatment of life-threatening PE in special populations are similar to that in the general population (see
         <a class="local">
          'Initial approach and resuscitation'
         </a>
         above and
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         above). However, definitive therapy may differ in hemodynamically stable patients with malignancy, pregnancy, and heparin-induced thrombocytopenia.
        </p>
        <p class="headingAnchor" id="H348157332">
         <span class="h3">
          Patients with malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In hemodynamically stable patients with malignancy and PE, LMW heparin and some of the direct oral anticoagulants,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , are used as anticoagulants. The details of supporting trials are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H348157350">
         <span class="h3">
          Patients who are pregnant
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most pregnant women with hemodynamically stable PE, adjusted-dose subcutaneous LMW heparin is the preferred agent for initial and long-term anticoagulation due to its favorable fetal safety profile  (
         <a class="graphic graphic_table graphicRef140440" href="/z/d/graphic/140440.html" rel="external">
          table 8
         </a>
         ). Treatment of PE in pregnancy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H348157378">
         <span class="h3">
          Patients with heparin-induced thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with PE and heparin-induced thrombocytopenia (HIT), all forms of heparin are contraindicated (eg, unfractionated and LMW heparin). Immediate anticoagulation with a fast-acting non heparin anticoagulant (eg,
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          argatroban
         </a>
         ) is indicated. The diagnosis and management of patients with HIT are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1166678555">
         <span class="h2">
          Inherited thrombophilias
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many cases, the presence of an inherited thrombophilia does not appreciably alter treatment decisions such as choice of an anticoagulant, but there may be specific circumstances in which the thrombophilia does affect management (eg, need for antithrombin [AT] administration in some individuals with AT deficiency). Details are presented in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factor V Leiden – (See
         <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">
          "Factor V Leiden and activated protein C resistance", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin G20210A mutation – (See
         <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">
          "Prothrombin G20210A", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein S deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">
          "Protein S deficiency", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein C deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Thromboembolism management'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antithrombin deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">
          "Antithrombin deficiency", section on 'VTE treatment (hereditary deficiency)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2559429676">
         <span class="h2">
          Antiphospholipid syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Considerations with treatment of VTE in patients with antiphospholipid syndrome are presented separately (eg, direct oral anticoagulants are generally not administered). (See
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H286669297">
         <span class="h1">
          ADJUNCTIVE THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapies that can be added as an adjunct to anticoagulation in patients with PE are discussed in the sections below.
        </p>
        <p class="headingAnchor" id="H112301711">
         <span class="h2">
          General medical
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PE should always receive supportive care with analgesia, intravenous fluids, and oxygen, as clinically indicated (see
         <a class="local">
          'Initial therapies'
         </a>
         above). When present, pleuritic pain from PE is best treated with scheduled medications, usually
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         or nonsteroidal antiinflammatories, and narcotics. The choice among these agents should be individualized. Failure to wean supportive therapies should prompt consideration of complications (eg, pneumonia or recurrence).
        </p>
        <p class="headingAnchor" id="H15616923">
         <span class="h2">
          Ambulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         When feasible, early ambulation should be encouraged in most patients with acute PE, provided the patient is
         <strong>
          definitively
         </strong>
         treated. For those with significant clot burden and significant PE, bedrest may be needed for the first 12 to 24 hours to ensure therapeutic anticoagulation. Typically, ambulation is limited by the need for postoperative bedrest or by comorbidities including severe symptoms of concurrent deep venous thrombosis (DVT) or hypoxia . (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Ambulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15617296">
         <span class="h2">
          Elastic graduated compression stockings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elastic graduated compression stockings (GCS) are not routinely used in patients with DVT to prevent post-thrombotic syndrome (PTS). Detailed discussion of the manifestations and treatment of post-thrombotic syndrome (PTS) and role of GCS in the prevention of PTS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Graduated compression stockings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8200.html" rel="external">
          "Post-thrombotic (postphlebitic) syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Inferior vena cava filters
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with acute PE, the primary indication for inferior vena cava (IVC) filter placement is when anticoagulation is contraindicated and when recurrent PE occurs despite therapeutic anticoagulation. However, it may be appropriate as an adjunct to anticoagulation in patients in whom another embolic event would be poorly tolerated (eg, poor cardiopulmonary reserve, or severe hemodynamic or respiratory compromise), although clinical data are lacking. Filters are not routinely placed as an adjunct in patients with PE. (See
         <a class="local">
          'Management of recurrence on therapy'
         </a>
         below.)
        </p>
        <p>
         Filter placement is also sometimes used in patients with recurrence despite therapeutic anticoagulation or in those with a high risk of recurrence in whom it is anticipated that anticoagulation may need to be discontinued because of bleeding. Examples include patients at moderate risk of bleeding who cannot receive fresh frozen plasma or red cells (eg, due to religious preference), and patients with metastatic malignancy who are at a high risk for both recurrence and bleeding.
        </p>
        <p>
         Although filters are not routinely placed as an adjunct in patients with PE, some experts place them in patients at risk of decompensation due to cardiorespiratory compromise. We agree that the adjunctive use of filters should not be routine, but placement may be individualized and should take into consideration the risk of recurrence and bleeding, patient preferences, institutional expertise, medical morbidities, and surgical complications.
        </p>
        <p>
         IVC filter placement in patients with contraindications to anticoagulation and filter complications are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p>
         A femoral IV access line with a "built-in" IVC filter that can be opened when the line is placed and collapsed and removed when the line is removed has been found useful in high risk patients who cannot be treated with anticoagulants [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8461870">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H286669997">
         <span class="h2">
          Morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognosis from PE is variable. Accurate estimates have been limited by data that are mostly derived from older studies, registries, and hospital discharge records collected from heterogeneous populations of patients. As an example, a patient with a single, asymptomatic, subsegmental PE (SSPE) likely has a different prognosis than a patient with massive PE and shock. However, in general, if left untreated, PE is associated with an overall mortality of up to 30 percent compared with 2 to 11 percent in those treated with anticoagulation [
         <a href="#rid1">
          1,4,57,110-116
         </a>
         ]. PE-related mortality may be decreasing with reported rates falling from 3.3 percent (2001 to 2005) to 1.8 percent (2010 to 2013) in one study and from 17 to 10 percent in another study [
         <a href="#rid116">
          116,117
         </a>
         ]. Another study that derived data from the World Health Organization (WHO) mortality database reported a similar decrease in deaths from 12.8 per 100,000 to 6.6 per 100,000 between 2000 and 2015 [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H286670153">
         <span class="h3">
          Early
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider early outcomes as those occurring within the first three months after the diagnosis of PE. The highest risk for events occurs within the first seven days; death and morbidity during this period are most commonly due to shock and recurrent PE.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shock (ie, hemodynamic collapse)
         </strong>
         – Shock can be the initial presentation or an early complication of PE (8 percent of patients). It is the most common cause of early death, particularly in the first seven days, and when present, is associated with a 30 to 50 percent risk of death [
         <a href="#rid112">
          112,113,119
         </a>
         ]. The high risk of death, which is greatest in the first two hours of presentation, is the rationale for the consideration of reperfusion therapy (thrombolytics/embolectomy) rather than anticoagulation. The risk remains elevated for 72 hours or more, such that close observation of this population, as well as those considered at risk of hemodynamic collapse (eg, right ventricle dysfunction), is prudent during hospitalization. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="local">
          'Embolectomy'
         </a>
         above and
         <a class="local">
          'Shock and right ventricular dysfunction'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence
         </strong>
         – The risk of recurrence (deep venous thrombosis [DVT] and PE) is greatest in the first two weeks, and declines thereafter. The cumulative proportion of patients with early recurrence while on anticoagulant therapy amounts to 2 percent at two weeks, and 6 percent at three months [
         <a href="#rid120">
          120-122
         </a>
         ]. Factors including cancer and failure to rapidly achieve therapeutic levels of anticoagulation are major predictors of increased risk of recurrence during this period, the management of which is discussed below [
         <a href="#rid123">
          123,124
         </a>
         ]. (See
         <a class="local">
          'Management of recurrence on therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pleuritic/alveolitis and pneumonia
         </strong>
         – In the one to two weeks following diagnosis, patients may deteriorate and develop worsening oxygenation, respiratory failure, hypotension, pain, and/or fever that suggests an evolving infarct and/or superimposed pneumonia. Although chest radiography may reveal collapse, atelectasis, or a pleural effusion to support the presence of an evolving infarct and/or superimposed pneumonia, these patients should undergo repeat definitive imaging (preferably with the original diagnostic imaging modality) to distinguish these diagnoses from recurrent PE. Patients without recurrence should be treated symptomatically with supplemental oxygen, analgesics, and intravenous fluids, and ventilation, vasopressors and/or antibiotics, as indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stroke
         </strong>
         – Prospective and retrospective studies have suggested an increased risk of stroke, thought to be due to paradoxical embolism via a patent foramen ovale (PFO), in patients with acute PE [
         <a href="#rid125">
          125-129
         </a>
         ]. Prevalence rates of stroke have ranged from 7 to 50 percent (averaging &lt;17 percent), with higher rates in those with PE who also have a PFO (21 to 64 percent, averaging &lt;33 percent). Best illustrating this risk for stroke is a prospective study of 361 patients with acute PE who underwent contrast transthoracic echocardiography (TTE) and magnetic resonance imaging (MRI) of the brain (for silent or symptomatic stroke) within ten days after the diagnosis of PE [
         <a href="#rid129">
          129
         </a>
         ]. Stroke was diagnosed in 7.6 percent and PFO in 13 percent of patients with acute PE. Rates of stroke were higher in those who had a PFO compared with those who did not have a PFO (21.4 versus 5.5 percent; relative risk 3.5, 95% CI 1.62-8.67). However, nine patients were excluded from the analysis due to inconclusive TTE or MRI testing and the rate of PFO was lower than that in the general population (approximately 25 to 30 percent) [
         <a href="#rid130">
          130
         </a>
         ] suggesting that these results are flawed. Further studies are recommended before we can support a recommendation to routinely perform contrast echocardiography (transthoracic or transesophageal) or MRI imaging in patients with acute PE who have no symptoms of stroke [
         <a href="#rid131">
          131
         </a>
         ]. Accordingly, we prefer a symptom-directed approach such that vigilant surveillance for neurologic symptoms is appropriate in those with acute PE and the presence of stroke should prompt a search for a PFO. Whether the discovery of a PFO with PE and stroke should prompt indefinite anticoagulation and/or PFO closure is also unknown such that a multidisciplinary approach with a pulmonologist, neurologist, and cardiologist is prudent. Management of patients with stroke and PFO is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1420.html" rel="external">
          "Patent foramen ovale"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">
          "Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">
          "Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H286670198">
         <span class="h3">
          Late
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of late events, at three months or later following a diagnosis of PE, ranges from 9 to 32 percent, with increased mortality reported for as long as 30 years [
         <a href="#rid1">
          1,4,114,115,132,133
         </a>
         ]. Late mortality is mostly due to predisposing comorbidities, and less commonly due to recurrent thromboembolism or chronic thromboembolic pulmonary hypertension. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality
         </strong>
         – In one retrospective study of 1023 patients with PE, the five-year cumulative mortality rate was 32 percent [
         <a href="#rid133">
          133
         </a>
         ]. Among those who died, only 5 percent of the deaths were due to PE, 64 percent were due to non-cardiovascular causes (eg, malignancy, sepsis), and 31 percent were due to cardiovascular causes other than PE (eg, myocardial infarction, heart failure, and stroke). One year follow-up of patients in the prospective investigation of PE diagnosis (PIOPED) cohort revealed similar findings [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another database analysis of over 128,000 patients with venous thromboembolism reported a three-fold increase in mortality at 30 years in patients with PE when compared with age and sex-matched controls who did not have PE during the same period [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Combined data from two prospective studies of 748 patients with PE reported that those with SSPE had similar rates of mortality (10 versus 7 percent) and recurrence (4 versus 3 percent) at three months when compared with patients with proximal PE [
         <a href="#rid57">
          57
         </a>
         ]. Death in patients with SSPE was largely determined by comorbidities including malignancy, increasing age, male sex, chronic obstructive pulmonary disease, and heart failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence
         </strong>
         – The cumulative rate of late recurrence has been reported to be 8 percent at six months, 13 percent at one year, 23 percent at five years, and 30 percent at 10 years [
         <a href="#rid120">
          120-122
         </a>
         ]. Rates of recurrence vary according to the population studied with comparable rates reported in those with SSPE and proximal PE at three months (4 versus 3 percent) [
         <a href="#rid57">
          57
         </a>
         ]. However, in general, the rate is lowered with therapeutic anticoagulation, and increased by the presence of select risk factors (eg, unprovoked PE, malignancy), which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH)
         </strong>
         – CTED and CTEPH are unusual complications of PE that typically present with progressive dyspnea within two years of the initial event. The clinical manifestations and diagnosis of CTED and CTEPH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – PE has been associated with an increased risk for subsequent cardiovascular events and atrial fibrillation [
         <a href="#rid134">
          134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'VTE and atherosclerotic disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For most patients with dyspnea, exercise capacity and quality of life improve over the first year. Predictors of reduced improvement over time in one prospective study of 100 patients with acute PE were female sex, higher body mass index, prior lung disease, and higher systolic pulmonary artery pressure on day 10 echocardiography [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The likelihood of complications and death from PE may be differentially dependent upon the presence or absence of provoking risk factors at the time of diagnosis. A three-year observational study that followed 308 patients with PE found that patients with unprovoked PE were more likely to develop recurrence, CTEPH, malignancy, and cardiovascular events; in contrast, patients who had provoked PE had a higher risk of death over the seven-year study period [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8463169">
         <span class="h2">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poor prognostic factors in patients diagnosed with PE are discussed in the sections below.
        </p>
        <p class="headingAnchor" id="H532211838">
         <span class="h3">
          Shock and right ventricular dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several clinical, radiologic, and laboratory markers of right ventricular (RV) dysfunction have been identified as poor prognosticators in patients with PE.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – The presence of clinical shock, which is due to severe RV failure, consistently predicts death in patients diagnosed with PE, the details of which are discussed above. (See
         <a class="local">
          'Early'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiologic (echocardiography and CT pulmonary angiography [CTPA])
         </strong>
         – RV dysfunction assessed by echocardiography or CT pulmonary angiography (CTPA), is associated with increased mortality [
         <a href="#rid137">
          137-143
         </a>
         ], although we believe that echocardiography is more reliable than CTPA.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One meta-analysis of seven studies that included 3395 normotensive and hypotensive patients with PE reported that RV dysfunction was associated with a two-fold increase in PE-related in-hospital mortality [
         <a href="#rid143">
          143
         </a>
         ]. However, a subgroup analysis of normotensive patients found that RV dysfunction on echocardiography or CT correlated poorly with mortality, suggesting that it is symptomatic RV dysfunction that predicts death.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 1950 patients diagnosed and treated with PE in a prospective multicenter trial, larger pulmonary trunk diameter on CTPA was associated with higher mortality during the treatment period of 3 to 6 months (OR 2.8, 95% CI 1.3-5.7) and at one year (OR 2.3, 95% CI 1.4-4.0) [
         <a href="#rid144">
          144
         </a>
         ]. An association with right ventricular dysfunction was not observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         RV dysfunction may also predict recurrent venous thromboembolism (VTE). In one prospective observational study of 301 patients with PE, those with persistent RV dysfunction on echocardiography at three months following diagnosis had a four-fold increased risk of recurrent VTE when compared with patients without RV dysfunction or with patients whose RV dysfunction resolved prior to discharge (9 versus 3 and 1 percent patient-years) [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Echocardiographic findings of RV dysfunction in patients with PE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Echocardiography'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83974.html" rel="external">
          "Echocardiographic assessment of the right heart", section on 'Conditions associated with right ventricular pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory markers
         </strong>
         – Biochemical markers of RV dysfunction at diagnosis include elevated levels of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) from RV strain
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Troponin-I and T levels due to RV-associated myocardial damage
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, elevated BNP, NT-proBNP, and troponin have consistently been associated with an increased risk of death or other adverse outcomes in patients with PE [
         <a href="#rid137">
          137,146-155
         </a>
         ]. However, the optimal cut-off values for risk stratification are unknown. In hemodynamically stable patients, these markers are poor predictors of death when elevated but consistently identify a benign clinical course when normal or low [
         <a href="#rid139">
          139,147,150,151,153,155-158
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         BNP and NT-proBNP as biomarkers of left heart failure and the differential diagnosis of elevated troponins, other than acute coronary syndrome, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1469.html" rel="external">
          "Elevated cardiac troponin concentration in the absence of an acute coronary syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H532212043">
         <span class="h3">
          Right ventricle thrombus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mobile right heart thrombi are seen in approximately 4 percent of patients with PE, by either echocardiography or CT, and the proportion is higher among patients who are critically ill (up to 18 percent) [
         <a href="#rid159">
          159,160
         </a>
         ]. The presence of right heart thrombus has been shown in several studies to be associated with RV dysfunction and high early mortality [
         <a href="#rid159">
          159,161,162
         </a>
         ]. As an example, data from an international registry of patients with PE reported that, compared with patients without RV thrombus, patients with RV thrombus had a higher 14-day mortality (21 versus 11 percent) and three-month mortality (29 versus 16 percent) [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H532211857">
         <span class="h3">
          Deep vein thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PE and a coexisting DVT are at increased risk for death. As an example, one prospective study of 707 patients with PE reported increased all-cause mortality (adjusted hazard ratio [HR] 2.05, 95% CI 1.24-3.38) and PE-specific mortality (adjusted HR 4.25, 95% CI 1.61-11.25) at three months in patients with concomitant DVT compared with those without concomitant DVT [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H532211936">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional predictors of poor prognosis that require further validation include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyponatremia (&lt;130 mmol/L) and indicators of renal dysfunction [
         <a href="#rid163">
          163-165
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum lactate (&gt;2 mmol/L) [
         <a href="#rid166">
          166,167
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White blood cell count (&gt;12.6 x 10
         <sup>
          9
         </sup>
         /L) [
         <a href="#rid168">
          168
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Charlson co-morbidity index ≥1 [
         <a href="#rid169">
          169
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual pulmonary vascular obstruction [
         <a href="#rid170">
          170,171
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age ≥65 years [
         <a href="#rid172">
          172
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor adherence to guidelines [
         <a href="#rid173">
          173
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachycardia on admission [
         <a href="#rid174">
          174
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute kidney injury [
         <a href="#rid175">
          175
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8462323">
         <span class="h2">
          Prognostic models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognostic models can facilitate the decision to treat patients as an outpatient and identify those that require vigilant monitoring as an inpatient. Their role in management outside of this context is unclear. (See
         <a class="local">
          'Outpatient anticoagulation'
         </a>
         above.)
        </p>
        <p>
         Several prognostic models have been derived in patients with acute PE, of which the Pulmonary Embolism Severity Index (PESI) and the simplified PESI (sPESI) are the most well-known  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid176">
          176-180
         </a>
         ]. While PESI and sPESI predict death, newer composite models predict death and/or complications (recurrent PE, hemodynamic collapse). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PESI
         </strong>
         – The PESI adds the patient's age to points assigned to ten additional variables  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid176">
          176
         </a>
         ]: male sex (+10 points), history of cancer (+30 points), heart failure (+10 points), chronic lung disease (+10 points), pulse ≥110 beats per minute (+20 points), systolic blood pressure &lt;100 mmHg (+30 points), respiratory rate ≥30 breaths per minute (+20 points), temperature &lt;36 degrees C (+20 points), altered mental status (+60 points), and arterial oxygen saturation &lt;90 percent (+20 points). The total score categorizes the patient according to increasing risk for mortality:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Class I (&lt;66 points)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Class II (66 to 85 points)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Class III (86 to 105 points)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Class IV (106 to 125 points)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Class V (&gt;125 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with class I/II are considered to be at low risk of death, compared with classes III through V, who are at high risk. The major limitation of the PESI is that it is difficult to apply in a busy clinical setting because so many variables must be considered, each with its own weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          sPESI
         </strong>
         – The sPESI assigns one point for each of the following variables: age &gt;80 years, a history of cancer, chronic cardiopulmonary disease, a heart rate ≥110 beats per minute, a systolic blood pressure &lt;100 mmHg, and an arterial oxyhemoglobin saturation &lt;90 percent [
         <a href="#rid181">
          181
         </a>
         ]. A score of zero indicates a low risk for mortality, while a score of one or more indicates a high risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The sPESI may have a prognostic accuracy that is similar to PESI. In a cohort of 995 patients with PE that compared PESI with sPESI, a similar 30-day mortality was reported in patients classified as low risk (3 versus 1 percent) or high risk (11 percent each) [
         <a href="#rid181">
          181
         </a>
         ]. Prospective validation of the sPESI is needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – A composite model that incorporates sPESI, brain natriuretic peptide (BNP), cardiac troponin I, and lower limb ultrasound (done within 48 hours of admission) was derived and validated in a cohort of 848 normotensive patients with acute PE [
         <a href="#rid179">
          179
         </a>
         ]. The combination of a low risk sPESI score and BNP &lt;100 pg/mL identified patients at low risk of death, hemodynamic collapse, and/or recurrent PE at 30 days (negative predictive value of 99 to 100 percent). The combination of high risk sPESI, elevated BNP, elevated troponin I, and concomitant DVT identified patients who were at high risk of death or complications at 30 days (positive predictive value, 21 to 26 percent). Further validation of this model is required before it can be routinely applied in clinical practice.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another score ("BOVA score") has also been described but requires further validation before it can be routinely used [
         <a href="#rid182">
          182
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         While many of the available prognostic models are sensitive in predicting death from acute PE, they are not specific. One study of 11 clinical prognostic models reported that although the sensitivity of some models, including PESI and sPESI, were &gt;89 percent, none had a specificity greater than 48 percent [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21434574">
         <span class="h1">
          MONITORING AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PE should be monitored following diagnosis for the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic levels of anticoagulation in patients receiving heparin and
         </strong>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         – The most common laboratory test used to monitor
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         is the activated partial thromboplastin time (aPTT) with a target range of 1.5 to 2.5 times the upper limit of normal. Some experts monitor heparin levels. Warfarin is monitored using the prothrombin time (PT) ratio usually expressed as the international normalized ratio (INR) with a goal INR of 2 to 3 (target 2.5). (See
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Low molecular weight heparin,
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , and the factor Xa and direct thrombin inhibitors do not require routine laboratory monitoring. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The development of conditions that affect the half-life of the anticoagulant used (eg, renal failure, pregnancy, weight gain/loss, drug interactions) should also be followed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early complications of PE, predominantly recurrence
         </strong>
         – In the one to two weeks following diagnosis, patients may deteriorate and experience recurrence, the management of which is discussed below. (See
         <a class="local">
          'Management of recurrence on therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether patients should undergo echocardiography (transthoracic or transesophageal) or MRI of the brain to look for a patent foramen ovale (PFO) or asymptomatic stroke is unclear. However, symptom-driven evaluation for a PFO and stroke is appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late complications of PE including recurrence and chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH)
         </strong>
         – At each visit, patients should be monitored for continued resolution of the presenting manifestations of PE and investigated for new symptoms suggestive of recurrent PE or deep venous thrombosis [
         <a href="#rid184">
          184
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The development of persistent or progressive dyspnea, particularly during the first three months to two years of diagnosis, should prompt the clinician to investigate for the development of CTEPH (affects up to 5 percent of patients). While some clinicians do not routinely perform follow-up CT, ventilation perfusion scans, or echocardiography, clinicians should have a low threshold to repeat diagnostic imaging if recurrence or CTEPH is suggested. In addition, some experts evaluate for CTEPH in those with risk factors. The risks, clinical manifestations and diagnosis of CTEPH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications of the therapy itself including bleeding and adverse effects of medications or devices
         </strong>
         – Patients should be monitored for complications including bleeding (anticoagulants), skin necrosis (
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ), osteoporosis (heparin), thrombocytopenia (heparin), and device migration (caval filters). Details regarding the individual complications of such therapies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Complications'
         </a>
         and
         <a class="local">
          'Embolectomy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The risk of recurrence and bleeding
         </strong>
         – The risk of recurrence and bleeding should be periodically reassessed in patients during and upon completion of therapy to assess the ongoing need for such treatment. As an example, patients with major bleeding while on anticoagulation should not continue, whereas those with minor bleeding (eg, epistaxis) or recurrence should continue to be anticoagulated. The indications for indefinite anticoagulation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The need for device removal
         </strong>
         – Patients who had an inferior vena cava filter placed because anticoagulation was contraindicated should, once the contraindication has resolved, initiate anticoagulant therapy and have the filter retrieved, if feasible. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Filter retrieval'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The underlying predisposing risk factors for PE
         </strong>
         – The presence or absence of risk factors that predisposed the patient to the development of PE (eg, malignancy, inherited thrombotic disorder, surgery) should be sought and investigated, as indicated. The evaluation of patients with established venous thromboembolism for risk factors is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In some institutions, specialty clinics follow patients with PE (eg, "clot clinic") to ensure adequate and thorough follow-up, although the benefits of such clinics are unknown.
        </p>
        <p class="headingAnchor" id="H21434792">
         <span class="h1">
          MANAGEMENT OF RECURRENCE ON THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadequate anticoagulation is the most common reason for recurrent venous thromboembolism (VTE; PE and/or deep venous thrombosis) while on therapy. Explanations for subtherapeutic anticoagulation as well as several additional etiologies for recurrence that should be considered are listed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subtherapeutic anticoagulation
         </strong>
         – Subtherapeutic anticoagulation is the most common reason for recurrence. A detailed history and examination should be performed to identify factors that contribute to subtherapeutic anticoagulation. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malabsorption (eg, malabsorption syndromes,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         should be taken with food) (see
         <a class="medical medical_review" href="/z/d/html/4781.html" rel="external">
          "Overview of nutrient absorption and etiopathogenesis of malabsorption"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Discontinuation for an anticipated procedure (see
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Poor compliance
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Altered dose requirement or pharmacokinetics for
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (eg, dietary vitamin K), target-specific oral anticoagulants (eg, drug interactions), or low molecular weight (LMW) heparin (eg, weight gain)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High dose requirement for heparin (eg, increased heparin binding proteins, aprotinin)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incorrect dosing of medication
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Consulting a coagulation specialist may be warranted, especially when abnormal pharmacokinetics or noncompliance for medications that cannot be monitored easily (eg, target-specific oral anticoagulants, LMW heparin) are suspected. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Heparin resistance/antithrombin deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those subtherapeutic on
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         , the dose should be increased to rapidly achieve therapeutic levels. For patients who are on LMW heparin or factor Xa and direct thrombin inhibitors in whom subtherapeutic anticoagulation is suspected but unconfirmed, or for those subtherapeutic on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , switching to a rapid–acting anticoagulant that can be followed (eg, unfractionated heparin) may be prudent while investigations are ongoing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because new direct thrombin and Xa inhibitors do not require monitoring, it is yet to be determined whether challenges will emerge with monitoring for therapeutic levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suboptimal therapy
         </strong>
         – Therapeutic anticoagulation is the optimal therapy for VTE. Suboptimal therapies, including inferior vena cava filters and embolectomy or thrombolysis not followed by anticoagulation, should be apparent to the investigating clinician. Resumption of therapeutic anticoagulation should be considered in such cases, when feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ongoing prothrombotic stimuli
         </strong>
         – In patients who develop recurrence
         <strong>
          despite
         </strong>
         therapeutic anticoagulation, a search for conditions associated with high recurrence rates is prudent. These include malignancy, May-Thurner syndrome, inherited thrombotic disorders (eg, protein S, protein C, or antithrombin deficiency), and antiphospholipid syndrome. (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'Anatomic risk factors for deep venous thrombosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In this population, therapeutic options are limited. We suggest an approach similar to that performed in patients with recurrent thrombosis who have an underlying malignancy. These options include treatment with an LMW heparin for those on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , escalation of the dose of LMW heparin for those on LMW heparin, and/or the addition of a vena cava filter. The efficacy of factor Xa and direct thrombin inhibitors in this population is unstudied. Further details regarding these strategies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome", section on 'Recurrent thromboembolism despite adequate anticoagulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Management of recurrence'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recurrence may also be associated with conditions that promote thrombus propagation (eg, mechanical obstruction of venous flow from pelvic masses or inferior vena cava filter), or thrombus dissociation (eg, large right ventricular [
         <a href="#rid185">
          185
         </a>
         ] or valvular thrombus). In such patients, treating the underlying cause or removing mobile thrombus may be appropriate, when feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Misdiagnosis
         </strong>
         – Occasionally, tumor or fat emboli may radiographically mimic PE due to thrombus, the presentation and management of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8252.html" rel="external">
          "Pulmonary tumor embolism and lymphangitic carcinomatosis in adults: Diagnostic evaluation and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1602.html" rel="external">
          "Fat embolism syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3879490180">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16922.html" rel="external">
          "Patient education: Pulmonary embolism (blood clot in the lung) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/696.html" rel="external">
          "Patient education: Pulmonary embolism (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial resuscitation
         </strong>
         – The initial approach to patients with
         <strong>
          suspected
         </strong>
         pulmonary embolism (PE) should focus upon stabilizing the patient while clinical evaluation and definitive diagnostic testing is ongoing  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ). (See
         <a class="local">
          'Initial approach and resuscitation'
         </a>
         above and
         <a class="local">
          'Initial therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Respiratory and hemodynamic support
         </strong>
         (see
         <a class="local">
          'Respiratory support'
         </a>
         above and
         <a class="local">
          'Hemodynamic support'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Supplemental oxygen should be administered to target an oxygen saturation ≥90 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe hypoxemia, hemodynamic collapse, or respiratory failure should prompt consideration of mechanical ventilation. When mechanical ventilation is necessary, we prefer that an expert in cardiovascular anesthesia be consulted, when feasible, to avoid catastrophic hypotension due to sedation and positive pressure ventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who require hemodynamic support, we suggest cautious infusions of intravenous fluid (IVF; 250 to 400 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) rather than larger volumes (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Vasopressor therapy should be initiated if perfusion fails to respond to IVF.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric anticoagulation
         </strong>
         – For patients with suspected PE who are hemodynamically
         <strong>
          stable
         </strong>
         or hemodynamically unstable and successfully resuscitated, the administration of empiric anticoagulation depends upon the risk of bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ), the clinical suspicion for PE ( (
         <a class="graphic graphic_table graphicRef54767" href="/z/d/graphic/54767.html" rel="external">
          table 2
         </a>
         ) (
         <a class="calc calc_professional" href="/z/d/html/13446.html" rel="external">
          calculator 1
         </a>
         )), and the expected timing of diagnostic tests (see
         <a class="local">
          'Hemodynamically stable'
         </a>
         above and
         <a class="local">
          'Empiric anticoagulation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with a
         <strong>
          low
         </strong>
         risk of bleeding and a high clinical suspicion for PE, we suggest empiric anticoagulation rather than waiting until definitive diagnostic tests are completed (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We use a similar approach in those with a moderate or low clinical suspicion for PE in whom the diagnostic evaluation is expected to take longer than four hours and 24 hours, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We do not anticoagulate patients with
         <strong>
          absolute contraindications
         </strong>
         to anticoagulant therapy or those with an
         <strong>
          unacceptably high
         </strong>
         risk of bleeding (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with a
         <strong>
          moderate
         </strong>
         risk of bleeding, empiric anticoagulant therapy may be administered on a case-by-case basis according to the assessed risk-benefit ratio  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The optimal agent for empiric anticoagulation depends upon hemodynamic instability, the anticipated need for procedures or thrombolysis, and the presence of risk factors and comorbidities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120060">
          (Related Pathway(s):
          <a class="utd-content-120060" href="/pathway/120060?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitive therapy
         </strong>
         <strong>
          for
         </strong>
         <strong>
          suspected PE
         </strong>
         – For those with
         <strong>
          suspected
         </strong>
         PE, we perform the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          •
         </span>
         In patients with a high clinical suspicion for PE who are hemodynamically
         <strong>
          unstable
         </strong>
         and who have a definitive diagnosis by portable perfusion scanning or a presumptive diagnosis of PE by bedside echocardiography (because definitive diagnostic testing is unsafe or not feasible), we suggest systemic thrombolytic therapy rather than empiric anticoagulation or no therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hemodynamically unstable'
         </a>
         above.)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120061">
          (Related Pathway(s):
          <a class="utd-content-120061" href="/pathway/120061?topicRef=8265&amp;source=see_link">
           Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If bedside testing is delayed or unavailable, the use of thrombolytic therapy as a life-saving measure should be individualized; if not used, the patient should receive empiric anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are hemodynamically unstable and the clinical suspicion is low or moderate, we suggest empiric anticoagulation similar to that suggested for patients who are hemodynamically stable; empiric thrombolysis is not justified in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The employment of a multidisciplinary team may be of value in patients who are unstable due to PE or in select patients with intermediate to high-risk PE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitive therapy for confirmed PE
         </strong>
         – For patients in whom the diagnostic evaluation
         <strong>
          confirms
         </strong>
         PE, we suggest an approach that is stratified according to whether or not the patient is hemodynamically stable or unstable  (
         <a class="graphic graphic_algorithm graphicRef57249 graphicRef99762" href="/z/d/graphic/57249.html" rel="external">
          algorithm 1A-B
         </a>
         ). At any time, the strategy may need to be redirected as complications of PE or therapy arise. (See
         <a class="local">
          'Definitive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically stable low-risk/nonmassive PE
         </strong>
         – For most hemodynamically
         <strong>
          stable
         </strong>
         patients with
         <strong>
         </strong>
         PE that is low risk/nonmassive, the following applies (see
         <a class="local">
          'Hemodynamically stable patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those in whom the risk of bleeding is low, we recommend that anticoagulant therapy be initiated or continued (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         )  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Outpatient anticoagulation is safe and effective in select patients at low risk of death  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         ), provided that they do not have respiratory distress, serious comorbidities, or requirement for oxygen or narcotics, and that they also have a good understanding of the risks and benefits of such an approach. (See
         <a class="local">
          'Outpatient anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Most patients with subsegmental PE should be anticoagulated; however, in a small select population, observation with serial lower extremity ultrasonography may be appropriate. (See
         <a class="local">
          'Patients with subsegmental PE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who have contraindications to anticoagulation or have an unacceptably high bleeding risk  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ), we suggest that an inferior vena cava (IVC) filter be placed rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Inferior vena cava filter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those in whom the risk of bleeding is moderate, therapy should be individualized according to the risk-benefit ratio and preferences of the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In most hemodynamically stable patients, we recommend
         <strong>
          against
         </strong>
         thrombolytic therapy (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically stable intermediate-risk/submassive PE
         </strong>
         – For most hemodynamically
         <strong>
          stable
         </strong>
         (ie, normotensive) patients with intermediate-risk/submassive PE, anticoagulation should be administered and patients monitored closely for deterioration. Examples of such patients include those who subsequently deteriorate due to recurrent PE, have a large clot burden, severe RV enlargement/dysfunction, have high oxygen requirement, and/or severely tachycardic  (
         <a class="graphic graphic_table graphicRef82171" href="/z/d/graphic/82171.html" rel="external">
          table 5
         </a>
         ). Thrombolysis and/or catheter-based therapies may be considered on a case-by-case basis when the benefits are assessed by the clinician to outweigh the risk of hemorrhage (eg, deterioration due to PE). (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically unstable PE
         </strong>
         – For most patients with hemodynamically
         <strong>
          unstable
         </strong>
         PE, the following applies (see
         <a class="local">
          'Hemodynamically unstable patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          No contraindications to thrombolysis
         </strong>
         – For patients with refractory hypotension and without contraindications to thrombolysis  (
         <a class="graphic graphic_table graphicRef95035" href="/z/d/graphic/95035.html" rel="external">
          table 7
         </a>
         ), we suggest systemic thrombolytic therapy followed by anticoagulation rather than anticoagulation alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         )  (
         <a class="graphic graphic_table graphicRef82171" href="/z/d/graphic/82171.html" rel="external">
          table 5
         </a>
         ). We suggest a similar approach for select patients whose course becomes complicated by hypotension during anticoagulation in whom the suspicion for recurrent PE despite anticoagulation is high. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="local">
          'Thrombolytic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Contraindications to thrombolysis
         </strong>
         – For those in whom thrombolysis is contraindicated  (
         <a class="graphic graphic_table graphicRef95035" href="/z/d/graphic/95035.html" rel="external">
          table 7
         </a>
         ), we suggest catheter or surgical embolectomy rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The choice between these options depends upon a variety of factors. (See
         <a class="local">
          'Embolectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Failed thrombolysis
         </strong>
         – For those in whom systemic thrombolysis is unsuccessful, the optimal therapy is unknown. Options include repeat systemic thrombolysis, catheter-directed thrombolysis, or catheter or surgical embolectomy. Our preference is for catheter-based thrombolysis. However, in many cases, the choice is dependent upon available resources and local expertise. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Hemodynamically unstable patients (high-risk pulmonary embolism)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjunctive therapies
         </strong>
         – In patients with PE who are fully anticoagulated, we suggest early ambulation rather than bedrest, when feasible (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although, IVC filters are not routinely used adjunctively in patients who are therapeutically anticoagulated, they are used in rare circumstances by some experts (eg, those with poor cardiorespiratory reserve), although this strategy is largely unproven. (See
         <a class="local">
          'Adjunctive therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – PE, left untreated, has a mortality of up to 30 percent, which is significantly reduced with anticoagulation. The highest risk occurs within the first seven days, with death most commonly due to shock. Prognostic models that incorporate clinical findings (eg, Pulmonary Embolism Severity Index [PESI] and the simplified PESI [sPESI]  (
         <a class="graphic graphic_table graphicRef90549" href="/z/d/graphic/90549.html" rel="external">
          table 6
         </a>
         )) and/or biochemical markers that indicate right ventricle strain (natriuretic peptides, troponin) can predict early death and/or recurrence. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Patients treated with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         and/or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         should be monitored for laboratory evidence of therapeutic efficacy. Patients should also be monitored for early (eg, recurrence) and late (eg, chronic thromboembolic pulmonary hypertension) complications of PE, as well as for the complications of anticoagulation and other definitive therapies. In addition, patients should be investigated for the underlying cause of PE. (See
         <a class="local">
          'Monitoring and follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of recurrence
         </strong>
         – Inadequate anticoagulation is the most common reason for recurrent venous thromboembolism while on therapy. The clinician should test for therapeutic levels of anticoagulants when relevant as well as considering additional etiologies of recurrence (eg, suboptimal therapy, ongoing prothrombotic stimuli, and alternate diagnoses). (See
         <a class="local">
          'Management of recurrence on therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1815596945">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Victor F Tapson, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DONALDSON GA, WILLIAMS C, SCANNELL JG, SHAW RS. A reappraisal of the application of the Trendelenburg operation to massive fatal embolism. Report of a successful pulmonary-artery thrombectomy using a cardiopulmonary bypass. N Engl J Med 1963; 268:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 163:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2018; 2:3226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4:4693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rali P, Sacher D, Rivera-Lebron B, et al. Interhospital Transfer of Patients With Acute Pulmonary Embolism: Challenges and Opportunities. Chest 2021; 160:1844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rali PM, Criner GJ. Submassive Pulmonary Embolism. Am J Respir Crit Care Med 2018; 198:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triantafyllou GA, O'Corragain O, Rivera-Lebron B, Rali P. Risk Stratification in Acute Pulmonary Embolism: The Latest Algorithms. Semin Respir Crit Care Med 2021; 42:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleitas Sosa D, Lehr AL, Zhao H, et al. Impact of pulmonary embolism response teams on acute pulmonary embolism: a systematic review and meta-analysis. Eur Respir Rev 2022; 31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabrhel C, Jaff MR, Channick RN, et al. A multidisciplinary pulmonary embolism response team. Chest 2013; 144:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudzinski DM, Piazza G. Multidisciplinary Pulmonary Embolism Response Teams. Circulation 2016; 133:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabrhel C, Rosovsky R, Channick R, et al. A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism. Chest 2016; 150:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhury P, Gadre SK, Schneider E, et al. Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes. Am J Cardiol 2019; 124:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll BJ, Beyer SE, Mehegan T, et al. Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team. Am J Med 2020; 133:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hobohm L, Farmakis IT, Keller K, et al. Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysis. Clin Res Cardiol 2023; 112:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathru M, Venus B, Smith RA, et al. Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. Crit Care Med 1986; 14:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molloy WD, Lee KY, Girling L, et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984; 130:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35:3033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulain T, Lanotte R, Legras A, Perrotin D. Efficacy of epinephrine therapy in shock complicating pulmonary embolism. Chest 1993; 104:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985; 13:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasu MA, O'Keefe DD, Kapellakis GZ, et al. Myocardial oxygen consumption: effects of epinephrine, isoproterenol, dopamine, norepinephrine, and dobutamine. Am J Physiol 1978; 235:H237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka H, Tajimi K, Matsumoto A, Kobayashi K. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: a comparison with those of dopamine and dobutamine. Clin Exp Pharmacol Physiol 1990; 17:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe MW, Saad RM, Spence TH. Hemodynamic effects of amrinone in a canine model of massive pulmonary embolism. Chest 1992; 102:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tu T, Toma C, Tapson VF, et al. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study. JACC Cardiovasc Interv 2019; 12:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashir R, Foster M, Iskander A, et al. Pharmacomechanical Catheter-Directed Thrombolysis With the Bashir Endovascular Catheter for Acute Pulmonary Embolism: The RESCUE Study. JACC Cardiovasc Interv 2022; 15:2427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baglin T. Fifty per cent of patients with pulmonary embolism can be treated as outpatients. J Thromb Haemost 2010; 8:2404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost 2010; 8:2406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erkens PM, Gandara E, Wells P, et al. Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost 2010; 8:2412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, Aujesky D, Díaz G, et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010; 181:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zondag W, Kooiman J, Klok FA, et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013; 42:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zondag W, Hiddinga BI, Crobach MJ, et al. Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism. Eur Respir J 2013; 41:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo HH, Queluz TH, El Dib R. Outpatient versus inpatient treatment for acute pulmonary embolism. Cochrane Database Syst Rev 2014; :CD010019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maestre A, Trujillo-Santos J, Riera-Mestre A, et al. Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. Ann Am Thorac Soc 2015; 12:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Exter PL, Zondag W, Klok FA, et al. Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. Am J Respir Crit Care Med 2016; 194:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard LSGE, Barden S, Condliffe R, et al. British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax 2018; 73:ii1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ, Broderick C. Outpatient versus inpatient treatment for acute pulmonary embolism. Cochrane Database Syst Rev 2019; 3:CD010019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy PM, Corsi DJ, Carrier M, et al. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. J Thromb Haemost 2017; 15:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank Peacock W, Coleman CI, Diercks DB, et al. Emergency Department Discharge of Pulmonary Embolus Patients. Acad Emerg Med 2018; 25:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barco S, Schmidtmann I, Ageno W, et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020; 41:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F, Hughes PG, et al. Home Treatment of Pulmonary Embolism in the Era of Novel Oral Anticoagulants. Am J Med 2016; 129:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinson DR, Mark DG, Chettipally UK, et al. Increasing Safe Outpatient Management of Emergency Department Patients With Pulmonary Embolism: A Controlled Pragmatic Trial. Ann Intern Med 2018; 169:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goy J, Lee J, Levine O, et al. Sub-segmental pulmonary embolism in three academic teaching hospitals: a review of management and outcomes. J Thromb Haemost 2015; 13:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bariteau A, Stewart LK, Emmett TW, Kline JA. Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment. Acad Emerg Med 2018; 25:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raslan IA, Chong J, Gallix B, et al. Rates of Overtreatment and Treatment-Related Adverse Effects Among Patients With Subsegmental Pulmonary Embolism. JAMA Intern Med 2018; 178:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost 2012; 10:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Goodman LR, Hull RD, et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost 2012; 18:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood 2013; 122:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gal G, Kovacs MJ, Bertoletti L, et al. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. Ann Intern Med 2022; 175:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ. Anticoagulant treatment for subsegmental pulmonary embolism. Cochrane Database Syst Rev 2020; 2:CD010222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouleau SG, Balasubramanian MJ, Huang J, et al. Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism. JAMA Netw Open 2023; 6:e2326898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 2015; 313:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 2012; 125:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isogai T, Yasunaga H, Matsui H, et al. Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic therapy. Am J Med 2015; 128:312.e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jara-Palomares L, Jiménez D, Bikdeli B, et al. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. Eur Respir J 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avgerinos ED, Jaber W, Lacomis J, et al. Randomized Trial Comparing Standard Versus Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism: The SUNSET sPE Trial. JACC Cardiovasc Interv 2021; 14:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koning R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation 1997; 96:2498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo WT, van den Bosch MAAJ, Hofmann LV, et al. Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis. Chest 2008; 134:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chechi T, Vecchio S, Spaziani G, et al. Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. Catheter Cardiovasc Interv 2009; 73:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margheri M, Vittori G, Vecchio S, et al. Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism. Am J Cardiol 2008; 101:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassiri N, Jain A, McPhee D, et al. Massive and submassive pulmonary embolism: experience with an algorithm for catheter-directed mechanical thrombectomy. Ann Vasc Surg 2012; 26:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrigno L, Bloch R, Threlkeld J, et al. Management of pulmonary embolism with rheolytic thrombectomy. Can Respir J 2011; 18:e52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brady AJ, Crake T, Oakley CM. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolus. Lancet 1991; 338:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz-Rode T, Janssens U, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000; 36:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eid-Lidt G, Gaspar J, Sandoval J, et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008; 134:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Hülsbeck S, Brossmann J, Jahnke T, et al. Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device. Invest Radiol 2001; 36:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reekers JA, Baarslag HJ, Koolen MG, et al. Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol 2003; 26:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation 2011; 124:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuculi F, Kobza R, Bergner M, Erne P. Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism. Am J Cardiol 2012; 110:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heberlein WE, Meek ME, Saleh O, et al. New generation aspiration catheter: Feasibility in the treatment of pulmonary embolism. World J Radiol 2013; 5:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley JR, Wible BC. In-Hospital Mortality and Related Outcomes for Elevated Risk Acute Pulmonary Embolism Treated With Mechanical Thrombectomy Versus Routine Care. J Intensive Care Med 2022; 37:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayen S, Upadhyay V, Kumaran M, et al. Changes in Lung Perfusion in Patients Treated with Percutaneous Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism. Am J Med 2022; 135:1016.
          </a>
         </li>
         <li class="breakAll">
          Cardiopulmonary Bypass Vascular Catheter, Cannula, Or Tubing. Food and Drug Administration; Department of Health and Human Services, Silver Spring, MD 2014.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz-Rode T, Günther RW, Pfeffer JG, et al. Acute massive pulmonary embolism: use of a rotatable pigtail catheter for diagnosis and fragmentation therapy. Radiology 1995; 197:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz-Rode T, Janssens U, Schild HH, et al. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest 1998; 114:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo WT, Gould MK, Louie JD, et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakazawa K, Tajima H, Murata S, et al. Catheter fragmentation of acute massive pulmonary thromboembolism: distal embolisation and pulmonary arterial pressure elevation. Br J Radiol 2008; 81:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar N, Janjigian Y, Schwartz DR. Paradoxical worsening of shock after the use of a percutaneous mechanical thrombectomy device in a postpartum patient with a massive pulmonary embolism. Chest 2007; 132:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Alnas M, Beemath A, Patel NR. Outcome of pulmonary embolectomy. Am J Cardiol 2007; 99:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osborne ZJ, Rossi P, Aucar J, et al. Surgical pulmonary embolectomy in a community hospital. Am J Surg 2014; 207:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keeling WB, Leshnower BG, Lasajanak Y, et al. Midterm benefits of surgical pulmonary embolectomy for acute pulmonary embolus on right ventricular function. J Thorac Cardiovasc Surg 2016; 152:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield P, Boon NA, de Bono DP. Indications for pulmonary embolectomy. Lancet 1988; 2:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F. Pulmonary embolectomy in elderly patients. Am J Med 2014; 127:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meneveau N, Séronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aymard T, Kadner A, Widmer A, et al. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy--should surgical indications be revisited? Eur J Cardiothorac Surg 2013; 43:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda I, Taniguchi S, Fukui K, et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg 2011; 91:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neely RC, Byrne JG, Gosev I, et al. Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. Ann Thorac Surg 2015; 100:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keeling WB, Sundt T, Leacche M, et al. Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study. Ann Thorac Surg 2016; 102:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy ED, Shah R, Hirji S, et al. National Outcomes of Surgical Embolectomy for Acute Pulmonary Embolism. Ann Thorac Surg 2020; 110:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg JB, Spevack DM, Ahsan S, et al. Survival and Right Ventricular Function After Surgical Management of Acute Pulmonary Embolism. J Am Coll Cardiol 2020; 76:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee T, Itagaki S, Chiang YP, et al. Survival and recurrence after acute pulmonary embolism treated with pulmonary embolectomy or thrombolysis in New York State, 1999 to 2013. J Thorac Cardiovasc Surg 2018; 155:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberger P, Shernan SK, Mihaljevic T, Eltzschig HK. Transesophageal echocardiography for detecting extrapulmonary thrombi during pulmonary embolectomy. Ann Thorac Surg 2004; 78:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg 2004; 77:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke DB, Abrams LD. Pulmonary embolectomy: a 25 year experience. J Thorac Cardiovasc Surg 1986; 92:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauphine C, Omari B. Pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg 2005; 79:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke DB. Pulmonary embolectomy re-evaluated. Ann R Coll Surg Engl 1981; 63:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matusov Y, Weinberg AS, Liang R, et al. Use of the Bedside-Placed Angel Catheter IVC Filter for Venous Thromboembolic Disease in Critically Ill Medical Patients. J Intensive Care Med 2020; 35:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijkeuter M, Söhne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest 2007; 131:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COON WW, WILLIS PW. Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment. Am J Cardiol 1959; 4:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soloff LA, Rodman T. Acute pulmonary embolism. II. Clinical. Am Heart J 1967; 74:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laporte S, Mismetti P, Décousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med 2006; 166:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides SV. Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news? Thromb Haemost 2016; 115:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, de Miguel-Díez J, Guijarro R, et al. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol 2016; 67:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barco S, Mahmoudpour SH, Valerio L, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2020; 8:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009; 29:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012; 87 Suppl 1:S63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170:1710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heit JA, Lahr BD, Petterson TM, et al. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118:4992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyen D, Castellani M, Moceri P, et al. Patent foramen ovale and stroke in intermediate-risk pulmonary embolism. Chest 2014; 146:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goliszek S, Wiśniewska M, Kurnicka K, et al. Patent foramen ovale increases the risk of acute ischemic stroke in patients with acute pulmonary embolism leading to right ventricular dysfunction. Thromb Res 2014; 134:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clergeau MR, Hamon M, Morello R, et al. Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study. Stroke 2009; 40:3758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vindiš D, Hutyra M, Šaňák D, et al. Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study. J Stroke Cerebrovasc Dis 2018; 27:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Moigne E, Timsit S, Ben Salem D, et al. Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study. Ann Intern Med 2019; 170:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 2006; 47:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lio KU, Jiménez D, Moores L, Rali P. Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke. Emerg Radiol 2020; 27:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Søgaard KK, Schmidt M, Pedersen L, et al. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 2014; 130:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng AC, Chung T, Yong AS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011; 4:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hald EM, Enga KF, Løchen ML, et al. Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study. J Am Heart Assoc 2014; 3:e000483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn SR, Akaberi A, Granton JT, et al. Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. Am J Med 2017; 130:990.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klok FA, Zondag W, van Kralingen KW, et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 2010; 181:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becattini C, Casazza F, Forgione C, et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013; 144:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo-Santos J, den Exter PL, Gómez V, et al. Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost 2013; 11:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coutance G, Cauderlier E, Ehtisham J, et al. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care 2011; 15:R103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becattini C, Agnelli G, Germini F, Vedovati MC. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J 2014; 43:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meinel FG, Nance JW Jr, Schoepf UJ, et al. Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis. Am J Med 2015; 128:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez O, Trinquart L, Planquette B, et al. Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. Eur Respir J 2013; 42:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ten Wolde M, Söhne M, Quak E, et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beenen LFM, Bossuyt PMM, Stoker J, Middeldorp S. Prognostic value of cardiovascular parameters in computed tomography pulmonary angiography in patients with acute pulmonary embolism. Eur Respir J 2018; 52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006; 166:2151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med 2008; 34:2147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lankeit M, Jiménez D, Kostrubiec M, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostrubiec M, Pruszczyk P, Bochowicz A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26:2166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janata KM, Leitner JM, Holzer-Richling N, et al. Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J 2009; 34:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lankeit M, Jiménez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124:2716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuilleumier N, Le Gal G, Verschuren F, et al. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 2009; 7:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lankeit M, Friesen D, Aschoff J, et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakemi EU, Alyousef T, Dang G, et al. The prognostic value of undetectable highly sensitive cardiac troponin I in patients with acute pulmonary embolism. Chest 2015; 147:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torbicki A, Galié N, Covezzoli A, et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003; 41:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casazza F, Bongarzoni A, Centonze F, Morpurgo M. Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997; 79:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollazadeh R, Ostovan MA, Abdi Ardekani AR. Right cardiac thrombus in transit among patients with pulmonary thromboemboli. Clin Cardiol 2009; 32:E27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002; 121:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherz N, Labarère J, Méan M, et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med 2010; 182:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostrubiec M, Łabyk A, Pedowska-Włoszek J, et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2010; 8:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostrubiec M, Łabyk A, Pedowska-Włoszek J, et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart 2012; 98:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanni S, Viviani G, Baioni M, et al. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. Ann Emerg Med 2013; 61:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanni S, Jiménez D, Nazerian P, et al. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax 2015; 70:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venetz C, Labarère J, Jiménez D, Aujesky D. White blood cell count and mortality in patients with acute pulmonary embolism. Am J Hematol 2013; 88:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng AC, Chow V, Yong AS, et al. Prognostic impact of the Charlson comorbidity index on mortality following acute pulmonary embolism. Respiration 2013; 85:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meneveau N, Ider O, Seronde MF, et al. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. Eur Heart J 2013; 34:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poli D, Cenci C, Antonucci E, et al. Risk of recurrence in patients with pulmonary embolism: predictive role of D-dimer and of residual perfusion defects on lung scintigraphy. Thromb Haemost 2013; 109:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cefalo P, Weinberg I, Hawkins BM, et al. A comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients &lt;65 years. Am J Cardiol 2015; 115:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, Bikdeli B, Barrios D, et al. Management appropriateness and outcomes of patients with acute pulmonary embolism. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaureguízar A, Jiménez D, Bikdeli B, et al. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest 2022; 161:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murgier M, Bertoletti L, Darmon M, et al. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. Int J Cardiol 2019; 291:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uresandi F, Otero R, Cayuela A, et al. [A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism]. Arch Bronconeumol 2007; 43:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, Kopecna D, Tapson V, et al. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2014; 189:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez D, Lobo JL, Fernandez-Golfin C, et al. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. Thromb Haemost 2016; 115:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bova C, Sanchez O, Prandoni P, et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; 44:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn CG, Mearns ES, Parker MW, et al. Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. Chest 2015; 147:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapson VF, Platt DM, Xia F, et al. Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM Study. Am J Med 2016; 129:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrios D, Rosa-Salazar V, Jiménez D, et al. Right heart thrombi in pulmonary embolism. Eur Respir J 2016; 48:1377.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8265 Version 103.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1560799" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The clinical course of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14028577" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A reappraisal of the application of the Trendelenburg operation to massive fatal embolism. Report of a successful pulmonary-artery thrombectomy using a cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18322285" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227218" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414967" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30482764" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31473594" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33007077" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34273391" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Interhospital Transfer of Patients With Acute Pulmonary Embolism: Challenges and Opportunities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29672125" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Submassive Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33548934" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk Stratification in Acute Pulmonary Embolism: The Latest Algorithms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904458" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35831010" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Impact of pulmonary embolism response teams on acute pulmonary embolism: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24189880" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A multidisciplinary pulmonary embolism response team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719388" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Multidisciplinary Pulmonary Embolism Response Teams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27006156" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31495443" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32416175" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35976429" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009801" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Management of massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6198941" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3080271" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6497165" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment of shock in a canine model of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173341" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8325096" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy of epinephrine therapy in shock complicating pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4064710" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Dobutamine: a hemodynamic evaluation in pulmonary embolism shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/686191" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Myocardial oxygen consumption: effects of epinephrine, isoproterenol, dopamine, norepinephrine, and dobutamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2272126" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: a comparison with those of dopamine and dobutamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623767" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hemodynamic effects of amrinone in a canine model of massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31072507" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36121244" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacomechanical Catheter-Directed Thrombolysis With the Bashir Endovascular Catheter for Acute Pulmonary Embolism: The RESCUE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21251192" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Fifty per cent of patients with pulmonary embolism can be treated as outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20626624" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ambulatory management of pulmonary embolism: a pragmatic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20735722" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Safety of outpatient treatment in acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21645235" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21703676" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20110556" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23100493" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22790909" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25411774" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Outpatient versus inpatient treatment for acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26114586" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27030891" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29898978" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30839095" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outpatient versus inpatient treatment for acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28106343" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29757489" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Emergency Department Discharge of Pulmonary Embolus Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31120118" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27107921" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Home Treatment of Pulmonary Embolism in the Era of Novel Oral Anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30422263" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Increasing Safe Outpatient Management of Emergency Department Patients With Pulmonary Embolism: A Controlled Pragmatic Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25442511" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sub-segmental pulmonary embolism in three academic teaching hospitals: a review of management and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29498138" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073241" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Rates of Overtreatment and Treatment-Related Adverse Effects Among Patients With Subsegmental Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22672341" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Symptomatic subsegmental pulmonary embolism: what is the next step?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21949040" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23736701" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34807722" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32030721" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Anticoagulant treatment for subsegmental pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37531107" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919526" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22310013" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24280176" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Vena cava filters in unstable elderly patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25446296" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32703772" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34167677" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Randomized Trial Comparing Standard Versus Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism: The SUNSET sPE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9355883" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18682455" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19235240" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18178417" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21885244" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Massive and submassive pulmonary embolism: experience with an algorithm for catheter-directed mechanical thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22059183" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Management of pulmonary embolism with rheolytic thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1682601" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10933345" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18198243" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Combined clot fragmentation and aspiration in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11410751" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14562972" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Mechanical thrombectomy for early treatment of massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22064957" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Catheter-based reperfusion treatment of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22980966" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24349647" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : New generation aspiration catheter: Feasibility in the treatment of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34397286" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : In-Hospital Mortality and Related Outcomes for Elevated Risk Acute Pulmonary Embolism Treated With Mechanical Thrombectomy Versus Routine Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35469736" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Changes in Lung Perfusion in Patients Treated with Percutaneous Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35469736" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Changes in Lung Perfusion in Patients Treated with Percutaneous Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7568815" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Acute massive pulmonary embolism: use of a rotatable pigtail catheter for diagnosis and fragmentation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9824024" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Fragmentation of massive pulmonary embolism using a pigtail rotation catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19875060" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18941044" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Catheter fragmentation of acute massive pulmonary thromboembolism: distal embolisation and pulmonary arterial pressure elevation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699140" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Paradoxical worsening of shock after the use of a percutaneous mechanical thrombectomy device in a postpartum patient with a massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11914247" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Acute pulmonary embolectomy: a contemporary approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261411" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Outcome of pulmonary embolectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24418179" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Surgical pulmonary embolectomy in a community hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26992603" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Midterm benefits of surgical pulmonary embolectomy for acute pulmonary embolus on right ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2899734" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Indications for pulmonary embolectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24333199" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Pulmonary embolectomy in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16608956" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Management of unsuccessful thrombolysis in acute massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15867775" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22466693" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy--should surgical indications be revisited?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21352987" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26165484" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27373187" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32199827" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : National Outcomes of Surgical Embolectomy for Acute Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32819463" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Survival and Right Ventricular Function After Surgical Management of Acute Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28942971" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Survival and recurrence after acute pulmonary embolism treated with pulmonary embolectomy or thrombolysis in New York State, 1999 to 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337008" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Transesophageal echocardiography for detecting extrapulmonary thrombi during pulmonary embolectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992879" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Open pulmonary embolectomy for treatment of major pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3747572" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Pulmonary embolectomy: a 25 year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15797055" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pulmonary embolectomy for acute massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7247257" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Pulmonary embolectomy re-evaluated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31994987" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Use of the Bedside-Placed Angel Catheter IVC Filter for Venous Thromboembolic Disease in Critically Ill Medical Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12885687" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296656" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13811755" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6073360" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Acute pulmonary embolism. II. Clinical.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347212" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16432084" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A prediction rule to identify low-risk patients with pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26632213" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791063" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31615719" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1089991" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Natural history of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131039" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Risk assessment for recurrent venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228602" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Venous thromboembolism: risk factors for recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367958" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Predicting the risk of venous thromboembolism recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20975016" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890644" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24874409" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Patent foramen ovale and stroke in intermediate-risk pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25282541" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Patent foramen ovale increases the risk of acute ischemic stroke in patients with acute pulmonary embolism leading to right ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797184" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29031497" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31060047" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412874" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32211984" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24970783" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : 30-year mortality after venous thromboembolism: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21098781" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24385452" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28400247" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965808" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23764909" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Acute pulmonary embolism: external validation of an integrated risk stratification model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23964984" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21443777" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24603813" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25680885" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23258789" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302640" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29773691" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Prognostic value of cardiovascular parameters in computed tomography pulmonary angiography in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060547" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18626627" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Natriuretic peptides in acute pulmonary embolism: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18556626" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19525265" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24627529" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12742987" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Prognostic role of brain natriuretic peptide in acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15911566" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Biomarker-based risk assessment model in acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606843" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Prognostic value of troponins in acute pulmonary embolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19465511" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19541721" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22082681" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19087222" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20584774" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25079900" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : The prognostic value of undetectable highly sensitive cardiac troponin I in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12821255" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9165180" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19330852" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Right cardiac thrombus in transit among patients with pulmonary thromboemboli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888964" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Treatment of right heart thromboemboli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595225" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Prognostic importance of hyponatremia in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20088923" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22705926" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23306454" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25661114" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23674436" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : White blood cell count and mortality in patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23147354" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Prognostic impact of the Charlson comorbidity index on mortality following acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103660" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23196319" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Risk of recurrence in patients with pulmonary embolism: predictive role of D-dimer and of residual perfusion defects on lung scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25586333" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : A comparison of patients diagnosed with pulmonary embolism who are≥65 years with patients&lt;65 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29724918" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Management appropriateness and outcomes of patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34478718" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31147192" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16020800" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Derivation and validation of a prognostic model for pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11057848" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983546" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : [A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24471575" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26738514" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696966" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24696111" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Identification of intermediate-risk patients with acute symptomatic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317677" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27046247" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27799388" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Right heart thrombi in pulmonary embolism.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
